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Selective Elimination of Malignant Melanoma Using the Novel Anti-tumor Agents,
OSW-1 and PEITC
Kausar Begam Riaz Ahmed, B. Tech., M.S.
(Advisory Professor: Peng Huang, M.D., Ph.D.)
Metastatic melanoma is amongst the most refractory of cancers. Drug resistance and
lack of therapeutic selectivity are two main challenges to successful melanoma therapy.
Herein, we investigated the mechanims of anticancer activity and therapeutic selectivity of
two

novel

agents,

3β,

16β,

17α-trihydroxycholest-5-en-22-one

16-O-[2-O-4-

methoxybenzoyl-β-D-xylopyranosyl]- [1→3]-2-O-acetyl-α-L-arabinopyranoside (OSW-1)
and β-Phenylethyl Isothiocyanate (PEITC) in melanoma.
OSW-1 inhibited melanoma cell viability at nanomolar concentrations with minimal
toxicity to normal melanocytes. Mechanistic studies revealed that OSW-1 suppressed
Disialoganglioside 3 Synthase (GD3S) gene expression in melanoma cells, leading to
inhibition of gangliosides GD3 and GD2. GD3 is an abundantly expressed melanoma cell
surface antigen with pivotal roles in cancer progression and invasion. OSW-1 promoted
interaction between GD3 and mitochondrial voltage-dependent gating protein 1 (VDAC1).
Subsequent VDAC1 activation and autophagic cell death was observed. Downregulation of
VDAC1 ameliorated the cytotoxic effect of OSW-1 in melanoma, indicating that VDAC1
was critical to mediating OSW-1’s activity. Studies with OSW-1 resistant melanoma cells
revealed that elevated ganglioside expression may form the mechanistic basis for the
selectivity of OSW-1 towards melanoma.
Melanoma cells are characterized by mitochondrial dysfunction and intrinsic
oxidative stress compared to normal melanocytes. Reactive oxygen species (ROS) activate
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pro-oncogenic signaling pathways that promote cancer progression and metastasis. However,
an excessive overload of ROS, beyond the cellular tolerance threshold may trigger oxidative
damage and cell death. The natural product PEITC induced apoptosis in malignant
melanoma. Biochemical studies revealed that PEITC depleted cellular glutathione leading to
ROS accumulation, mitochondrial damage and cell death. Glutathione inhibition was crucial
to mediating PEITC’s activity since the glutathione precursor, N-Acetyl Cysteine reversed
ROS elevation and PEITC induced death. Normal melanocytes with a much lower basal ROS
capacity were resistant to PEITC. Drug combination effect of PEITC with Carmustine and
Temozolomide was synergistic, suggesting that redox modulating strategies may be effective
in attenuating chemoresistance to these agents.
My study outlines novel therapeutic strategies to effectively eliminate malignant
melanomas. The intrinsic differences in ganglioside expression and redox status between
normal and cancer cells may be exploited to selectively kill melanoma cells using OSW-1
and PEITC, thus making these compounds worthy of further pre-clinical and clinical
investigation.
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Chapter 1: Introduction
1.1 Metabolic and biochemical alterations in melanoma
1.1.1 Dysregulated lipid metabolism: role of gangliosides.
Altered metabolism is a hallmark of cancer cells (1, 2). In addition to exhibiting the
warburg effect phenotype, aggressive cancers are also characterized by increased de novo
lipogenesis which provides membrane building blocks for rapid proliferation, posttranslational protein modifications and cell signaling (3). The expression of critical lipogenic
enzymes such as fatty acid synthase (FASN), HMG Co-A reductase (HMGCR), acetyl-coA
carboxylase (ACC) is upregulated in human cancers, including malignant melanoma (4, 5).
Increased expression of the key fatty acid synthesis enzyme, FASN is correlated with
poor prognosis in breast cancer and melanoma (6, 7). Elevated fatty acid synthesis has been
associated with a high proliferative index in prostate cancers (8). Aberrant fatty acid
biosynthesis induced by FASN overexpression has been known to induce a cancer-like
phenotype in non-cancer epithelial cells (9). Further, oncogenic signaling pathways also
activated FASN leading to increased fatty acid biosynthesis. Yamauchi et al. (2011)
demonstrated that the PI3K-Akt-mTORC1 oncogenic signaling in melanoma cells activates
the steroid regulatory element binding protein (SREBP), which is the master transcription
factor for lipid metabolism (10). SREBP, in turn, activates the downstream HMGCR enzyme
leading to increased cholesterol biosynthesis. Inhibition of the PI3K-Akt-mTORC1-SREBP
signaling axis resulted in reduced cholesterol levels in the cell membrane lipid rafts.
Importantly,

inhibition

of

this

SREBP

mediated

cholesterol

biosynthesis

using

pharmacological inhibitors suppressed Akt activation in lipid rafts and attenuated tumor
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growth (10). Ganglioside GD3 positively regulated the lipogenic phenotype in melanoma
cells by mediating Akt activation and thus the downstream cholesterol biosynthesis.
Gangliosides are sialic acid containing glycosphingolipids that are ubiquitously
expressed in human cancers and regulate signals transduced at the membrane microdomains
(11). In general, while disialic acid containing gangliosides (GD3, GD2, GD1) promote
tumor cell proliferation, invasion and motility and are considered to be pro-oncogenic (11,
12), monosialic acid containing gangliosides (GM3, GM2, GM1) are tumor suppressive and
inhibit cell growth and metastasis (11, 13, 14). In melanoma, elevated levels of gangliosides
GD3, GD2, GM3 and GM2 were reported (15). Normal melanocytes exhibited high
expression of ganglioside GM3 and minimal levels of GD3 (16). This differential ganglioside
expression was due to a very low expression of the GD3 synthesis regulating enzyme GD3
synthase in normal melanocytes (16). Using GD3-negative mutant of SK-MEL-28 cells,
Furukawa et al. (2011), demonstrated that GD3 expression contributed to increased
phosphorylation of adaptor molecules, p130Cas, paxillin, and focal adhesion kinase (FAK).
Further, higher localization of the Src kinase, Yes, to the lipid rafts in the cell membrane of
GD3-positive SK-MEL-28 cells was observed. Also, enhanced integrin function and a higher
localization of integrin to the ganglioside enriched microdomains (GEM)/lipid rafts in the
GD3-positive SK-MEL-28 cells, where it clusters with GD3 on the rafts, was observed. (1719). Thus ganglioside GD3 acts as a point of convergence for growth factor receptormediated signaling and integrin mediated adhesion signaling, leading to activation of
enhanced malignant signals and cancer phenotypes (figure 1.1) (18, 20). More significantly,
injection of anti-GD3 monoclonal antibody suppressed tumor progression in melanoma
tissues and patients making it an important target for melanoma therapy (21, 22).
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The ganglioside GD2 is overexpressed in breast and lung cancers. Battula et al.
reported that GD2 is a stem cell marker in human breast cancer and may contribute to c-Met
activation and chemoresistance in these cells (23, 24). Anti-GD2 antibody treatment of small
cell lung cancer (SCLC) cells led to dephosphorylation of FAK, activation of p38 MAPK and
finally cell death by anoikis (25).
Majority of gangliosides are constituted in the lipid rafts, where they interact with the
receptors and other downstream proteins. It was observed that overexpression of the lipid
raft-resident protein, caveolin-1, led to the dispersion of GD3 from the lipid raft domains
(26). Further, the fine structure in the ceramide group of GD3 expressed in lipid raft was
reported to be different from GD3 located in non-raft cell fractions (26). Further, a
translocation of GD3 to the mitochondria during cell death signaling, where it regulates
microtubule polymerization and apoptotic induction, has also been reported (27). Further
studies need to be undertaken to shed light on the complex roles of GD3 in melanoma
biology.
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Figure 1.1:

Figure 1.1: Convergence of growth factor receptor-mediated and integrin mediated
adhesion signaling pathways under GD3 expression in melanoma.
Reprinted by permission of Oxford University Press on behalf of the Japanese Biochemical
Society.
(11): Furukawa K, Hamamura K, Ohkawa Y, Ohmi Y. Disialyl gangliosides enhance tumor
phenotypes with differential modalities. Glycoconjugate journal. 2012;29(8-9):579-84.

4

1.1.2 Mitochondrial dysfunction
Mitochondria are dynamic cellular organelles which act as functional sites for
oxidative phosphorylation, fatty acid oxidation, tricarboxylic acid cycle and execution of
apoptosis (28, 29). Cancer cells are characterized by Warburg effect, wherein the tumor cells
rely on glycolysis rather than oxidative phosphorylation for their energy and metabolic needs
due to defects in their mitochondrial respiratory machinery, decreased oxidation of NADHlinked substrates or mitochondrial mutations. Increase in reactive oxygen species (ROS), due
to various causes such as defects in electron transport, reduced ROS scavenging,
environmental or oncogene induced stress etc., is a characteristic feature of cancer cell
mitochondria (28). Enhanced ROS contributes to stabilization of hypoxia inducible factor-α,
loss of p16, further oxidative damage and metastasis of cancer cells. In addition, mutations in
mitochondrial DNA have also been observed. For instance, Tan et al. (2002) identified
somatic mutations in the D-loop region, 16sRNA, ND2 and ATPase 6 genes of mitochondrial
DNA in breast cancer patients (29, 30). In melanoma, a comprehensive analysis by Poetsch
et al. (2004) discovered mitochondrial instability in the D-loop region in 13% of nodular
primary cancers and 20% metastatic melanomas (31). Interestingly, the pro-oncogenic
mutant BRAF, BRAF V600E localized to mitochondria in thyroid cancer cells leading to
inhibition of oxidative phosphorylation, increased glycolytic activity and a high glucose
uptake (32).
Mitochondrial autophagy or mitophagy is also activated in cancer cells as a cellular
response mechanism to nutrient depletion (28). Various studies indicate that mitophagy is
preceded

by

mitochondrial

fragmentation

and

membrane

permeabilization.

The

mitochondrial transition pore protein, voltage dependent anion channel 1 (VDAC1) has been
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reported to induce apoptotic and autophagic cell death in cells (33-35). Recent studies by De
Pinto et al. (2007) and Tomasello et al (2009) demonstrated that overexpression of human
(h)VDAC1 caused depolarization of the inner membrane and triggered mitochondrial
permeability transition (MPT), which may be followed by autophagy (33, 36). In cancer
cells, the hypoxia regulated BNIP3/NIX proteins have been recognized as key players in
mediating mitochondrial autophagy (28, 37).
1.1.3 Redox homeostasis and oxidative stress
A unique feature of melanoma biology is the free radical generation by aberrant
melanosomes (38). Reactive oxygen species play important roles in melanoma development,
immune response, metabolism, and metastasis (38). Loss of PTEN and decreased PTEN
activity is observed in about 20% of melanomas (39). Activation of Akt signaling can
promote ROS generation by inducing the expression of the ROS generating enzyme NOX4
in melanoma cells and mice (40). Also, Akt may inhibit the activity of various pro-apoptotic
proteins such as BAD and forkhead transcription factor (FOXO) thus stabilizing the cells
with mitochondrial damage and potentiating ROS production. Further, MAPK which are
activated in melanoma due to BRAF V600E activating mutation also modulate ROS
generation in cells (41, 42). Further loss of function of the tumor suppressors, p53 and p16
may also contribute to ROS stress phenotype (43). Chronic oxidative stress in combination
with ultraviolet (UV) exposure may lead to malignant transformation of cells (38, 44, 45).
ROS can activate the transcription factors, NF-κB and AP-1 thus promoting melanoma
progression (46, 47). ROS generated by hypoxic mitochondria and NADPH oxidases may
stabilize hypoxia inducible factor 1-α (HIF1-α) and potentially block PTEN mediated
inhibition of Akt signaling leading to activation of downstream anti-apoptotic proteins
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including Bcl-1 and Bcl-xL (48). Thus ROS plays pivotal roles in melanoma transformation
and metastasis.
Reactive oxygen species function as a doubled-edged sword. Intrinsically high ROS
levels in melanoma cells promote tumor development. However, if the ROS stress in
melanoma is at a level that is beyond the cell’s toxicity tolerance threshold, then it may
trigger cell death. Normal cells which have lower basal ROS stress levels and a reserve
antioxidant capacity will be resistant to this ROS accretion since their antioxidants will be
mobilized to neutralize the ROS increase and prevent it from reaching the cell-death
threshold. The pro-oncogenic signaling in melanoma cells triggers increased ROS production
and elevates the antioxidant capacity of the cells so as to neutralize the high level of free
radicals being generated. Eventually, this results in a shift of redox dynamics and a high
dependence of cancer on antioxidants to sustain the ROS levels within the cell’s toxicity
threshold (49). Hence cancer cells are more vulnerable to redox modulatory or pro-oxidant
based therapeutic strategies that by either scavenging the antioxidants or instigating
excessive ROS production (for instance through inhibition of oxidative phosphorylation) may
drive the ROS levels above the toxicity tolerance threshold of the cell leading to massive cell
death (49). This therapeutic strategy is illustrated in figure 2.
This therapeutic strategy is relatively novel and may find great utility in inducing cell
death as well as combating drug resistance to other conventional melanoma
chemotherapeutic agents. Currently, Elesclomal, a pro-oxidant compound that utilizes a
similar mechanism of action is in clinical trials for melanoma (50-52).
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Figure 1.2:

Figure 1.2: Altered redox dynamics between normal and cancer cells.
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery,
copyright 2009.
(49): Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated
mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009;8(7):57991.
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1.2 Purpose and significance of this study
The purpose of this PhD dissertation was to characterize novel therapeutic strategies
based on altered lipid metabolism and reactive oxygen species mediated stress in melanoma
cells to selectively eliminate malignant melanomas using the novel anticancer agents, OSW-1
and PEITC.
The rationale for this research design, study hypothesis and specific aims have been
described in the sections below.
1.2.1 Rationale for this study
Selective elimination of malignant melanomas by OSW-1:
The ganglioside GD3 is highly expressed in a majority of melanoma cell lines and
tissues (53, 54) and mediates cell proliferation and metastasis (17, 19). Hamamura et al.
(2005) demonstrated that GD3 enhanced cell growth and invasion through FAK, p130cas and
paxicillin signaling in melanoma cells (17). Enhanced integrin cluster formation in lipid rafts
on the melanoma cell membrane was observed under GD3 expression suggesting that it
contributed to adhesion signaling in malignant melanoma (19). Thus GD3 acts as a
convergence point for growth factor and integrin-mediated adhesion signaling in melanoma
cells (18, 20). Further, GD3 expression induced cholesterol biosynthesis, lipogenic
phenotype and activation of Akt signaling in melanoma (10). Significantly, only trace
amounts of GD3 were detected in normal melanocytes as compared to melanoma cells (16),
thus highlighting its potential as a surface antigen that can be targeted to selectively eliminate
melanoma cells with limited toxicity to the surrounding normal melanocytes. Currently, GD3
is being investigated in melanoma immunotherapy (21, 22, 55).
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Recent studies identified that Triptolide, which bears structural similarities with
OSW-1, inhibited ganglioside GD3 and GD2 expression in melanoma cells (56). Yokoyama
et al. (2005), discovered that OSW-1 encapsulation in GM3 liposomes led to melanoma cell
killing (57). These results suggested that OSW-1 might potentially inhibit ganglioside
expression in melanoma cells. Previous studies from our lab have demonstrated that OSW-1
induces cytotoxicity through mitochondrial dependent mechanisms in leukemia cells (58,
59). Ganglioside GD3 translocates to mitochondria during cell death and through its
interactions with the raft-like mitochondrial microdomains may have a regulatory function in
inducing mitochondrial membrane permeabilization and apoptosis (27, 60).
The rationale for my research study was that OSW-1, because of its similarity to
Triptolide and higher affinity towards GM3 may have an inhibitory effect on ganglioside
(GM3, GD3, GD2) expression. Inhibition of ganglioside GD3, which plays important roles in
melanoma proliferation and invasion, would promote melanoma cell death. Further, because
of the melanoma cell specific expression of GD3, cell death due to GD3 inhibition by OSW1 may be selective towards cancer cells. It was essential to investigate the effect of GD3 in
mitochondrial signaling since OSW-1 was previously to act through mitochondria dependent
mechanisms.
Effective elimination of melanoma by PEITC:
Increased ROS generation and altered redox status is observed in cancer cells
compared to normal cells. Recent studies have suggested that this differential redox biology
may be exploited to selectively target malignant cells, overcome drug resistance and improve
the therapeutic activity of current clinically available anticancer agents (61).
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Melanoma cells are under a higher intrinsic oxidative stress compared to normal
melanocytes due to oncogene activation and aberrant melanosome function (62). This
elevated ROS promotes melanoma oncogenic transformation, invasion, metastasis and
metabolism. However, if the ROS stress in cells is pushed beyond the cells’ tolerance limit
either by using pro-oxidant compounds or by abrogating the cellular antioxidant capacity, it
would lead to massive toxicity and cell death.
The anticancer agent PEITC causes ROS accumulation in cancer cells either through
depletion of the antioxidant glutathione or by inhibiting oxidative phosphorylation (63, 64).
In my research, I postulated that melanoma cells would be at a higher intrinsic oxidative
stress than normal melanocytes, making them vulnerable to ROS stress based therapeutic
strategies. PEITC, because of its ability to potentiate further ROS increase, will effectively
eliminate melanoma cells. Normal melanocytes, which maintain basal redox homeostasis,
will be able to withstand the exogenous ROS stress induced by PEITC to a certain extent,
and thus would be less sensitive to PEITC or other redox modulating agents. Further, these
principles of redox modulation by PEITC may be utilized in attenuating drug resistance to
currently used anticancer agents such as Temozolomide and Carmustine.
1.2.2 Background information on OSW-1
The natural product, 3β, 16β, 17α-trihydroxycholest-5-en-22-one 16-O-[2-O-4methoxybenzoyl-β-D-xylopyranosyl]- [1→3]-2-O-acetyl-α-L-arabinopyranoside (OSW-1),
an acylated disaccharide cholestane saponin molecule was originally isolated as a main
constituent of the bulbs of Ornithogalum saundersiae (Liliaceae) (65-67). It is highly
cytotoxic against several human cancer cell lines with half maximal inhibitory concentrations
in the nanomolar range (58, 59, 68). It exhibited significantly higher inhibitory effect than
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many clinically used anticancer agents including etoposide, adriamycin (ADM), taxol
(TAX), cisplatin (CDDP), mitomycin c and methotrexate (MTX) in leukemia, pulmonary
adenocarcinoma, mouse mastrocarcinoma, pancreatic and brain cancers (59, 67).
Importantly,

adriamycin-resistant and camptothecin-resistant p388 leukemia as well as

fludarabine refractory primary leukemia cells from chronic lymphocytic leukemia (CLL)
patients were sensitive to OSW-1 suggesting that it had a unique mechanism of action that
was different from these clinically used agents (59, 67). In vivo evaluation showed that it
was extremely potent against mouse p388 tumors with a single 0.01 mg/kg dose increasing
life span by 59% (67). Importantly, OSW-1 was therapeutically selective towards malignant
cells with half-maximal inhibitory concentrations (IC50) 40- to 150-fold higher in normal
cells than cancer cells (59).
An in vitro screen against the National Cancer Institute (NCI)-60 cell line panel
indicated that OSW-1 exhibited significant toxicity with an IC50 of 0.78 nM (67). Melanoma
cells were specifically sensitive to OSW-1. Further Pearson’s correlation analysis using
NCI’s COMPARE algorithm generated a Pearson’s correlation co-efficient between 0.6 and
0.83 for OSW-1 vs. cephalostatin 1 suggesting that they had related mechanisms of action
and shared cellular targets (67, 69). Structure activity relationship (SAR) analysis by Guo et
al., identified that OSW-1 was analogous to one-half of the cephalostatin molecule with C22oxocarbenium ions playing a common role in the bioactivity of both OSW-1 and
cephalostatin (68). Structural studies also revealed that the acetyl (Ac) and the 4methoxybenzoyl (MBz) groups on the disaccharide moiety of OSW-1 were essential as their
removal diminished its cytotoxicity by 1000 fold (67, 70). In addition, the steroidal aglycone
was critical to OSW-1’s potent cytotoxicity since SAR analysis indicated that substituting the
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aglycone group on the steroidal backbone of OSW-1 with a totally disparate synthetic
aglycone, while still retaining the disaccharide moiety, resulted in the compound not
exhibiting any cytotoxic effects even at a concentration of 10 µM (66, 68, 71, 72). Thus both
the disaccharide and aglycone groups are important to the antineoplastic activity of OSW-1.
The first chemical synthesis of OSW-1 was reported by Deng et al. (1999), with an overall
yield of 6% and 14 steps (73). Later, Yu et al. (2002), published an improvised synthesis
procedure which reduced the total chemical synthesis steps to 10 and improved the overall
yield to 28% (74). These findings inspired several studies on the synthesis and in vitro
cytotoxic activity of OSW-1 analogues. Of specific interest to this dissertation, is the
synthesis of biotinylated OSW-1 which is 10-times less toxic to cells than OSW-1 and may
be used as a tool to identify the cellular interacting partners of OSW-1 (75).

13

Figure1.3: Structure of OSW-1.
Chemical formula: C47H68O15
Molecular weight: 873.03
Reprinted by permission from Macmillan Publishers Ltd: Nature Chemical Biology
copyright 2011.
(69): Burgett AW, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K,
Okubo S, Fortner KC, Mimaki Y, Kuroda M, Murphy JP, Schwalb DJ, Petrella EC, CornellaTaracido I, Schirle M, Tallarico JA, Shair MD. Natural products reveal cancer cell
dependence on oxysterol-binding proteins. Nature chemical biology. 2011;7(9):639-47.
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Despite numerous studies on the chemical synthesis, bioactivity and structure activity
relationship (SAR) of OSW-1 and its analogues, the mechanisms underlying the antitumor
effect of this inhibitor are still not completely understood (67, 73-79). Tamura et al.,
demonstrated that OSW-1 directly inhibited gene expression of the ovarian steroidal limiting
enzyme, cholesterol side chain cleavage cytochrome P-450 (p450scc), leading to suppression
of ovarian estradiol secretion and granulosa cells proliferation in the ovary (80). Mechanistic
studies from our lab revealed that OSW-1 inhibited the sodium-calcium exchanger 1 (NCX1)
on the plasma membrane of leukemia cells, leading to cellular calcium overload, cytochrome
c release and mitochondria dependent apoptosis (58). The mitochondrial respiration deficient
human leukemia cells (HL60 C6F) were less sensitive to OSW-1 than the parental HL60
cells, suggesting that OSW-1 mediated cell death was through mitochondria dependent
mechanisms. Burgett et al. (2011), identified the oxysterol binding protein (OSBP) and its
closest paralog, OSBP-related protein 4L (ORP4L) as cellular binding targets of OSW-1 and
cephalostatin, thus implying a role for these compounds in signal transduction, lipid transport
and lipid metabolism (69). OSW-1 also induced necroptotic death in hepatocellular
carcinoma through inhibition of cell invasiveness, angiogenesis, cell polarity and adhesion
signaling, in addition to promoting mitochondria dependent apoptosis (81). Recently Yamada
et al., identified endoplasmic reticulum (ER), golgi apparatus and to a lesser extent
mitochondria as putative subcellular sites of OSW-1 localization (82).
Atomic force microscopy studies by Yokoyama et al. (2005), identified that OSW-1
distributed in the ganglioside GM3-phospholipid membrane monolayer in cells (83). Further,
a strong attractive interaction between OSW-1 and GM3 was observed which seemed to be
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related to the potent activity of OSW-1 against cancer cells. Specifically, treatment of B16F0 melanoma cells with OSW-1 encapsulated in ganglioside GM3 liposomes led to a
complete inhibition of cell viability within 48 h (57). Interestingly, Triptolide, a structural
analogue of OSW-1, suppressed the gene expression of GD3 synthase (GD3S), the rate
limiting enzyme for GD3 biosynthesis, in melanoma and breast cancer cells (24, 56).
Gangliosides are glycosphingolipids containing sialic acids which have been reported to be
overexpressed in carcinomas of the lung, breast, neuroblastoma and melanoma (24, 53, 54,
84-86). Ganglioside, GD3 is overexpressed in melanoma and is a well characterized
therapeutic target (21).
These research findings describe a role for OSW-1 in ganglioside biology and
mitochondria dependent cell signaling. Through my PhD research, I sought to investigate the
effect of OSW-1 on ganglioside GM3/GD3 expression and mechanisms of mitochondria
dependent cell death in melanoma cells. Further, I conducted mechanistic studies to delineate
the molecular mechanisms underlying the therapeutic selectivity of OSW-1 towards
melanoma cells. The results and discussion in Chapter 3 focus on the important outcomes of
my research with the antitumor agent OSW-1 in melanoma.
1.2.3 Background information on PEITC
The natural product β-Phenylethyl Isothiocyanate (PEITC) is an active metabolite of
cruciferous vegetables such as broccoli, cauliflower and watercress (87). It exhibits
chemopreventive properties by inhibiting the activity of the transcription factor, Nuclear
Factor κB (NF-κB), which plays an important role in inflammation, cancer progression and
survival. NF-κB is regulated by the protein IκBα, which sequesters NF-κB in the cytosol thus
preventing its nuclear translocation and activation of downstream pro-inflammatory and
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oncogenic genes (88). IκBα is a well characterized target of PEITC in prostate cancer (89).
PEITC stabilizes IκBα expression thus inhibiting NF-κB activation, nuclear translocation of
p65, and promotes suppression of NF-κB mediated VEGF, cyclin D1, Bcl-xL, iNOS and
COX-2 protein expression (89-91).
Numerous studies have reported that PEITC induces apoptosis in cancer cells, both in
in vitro and in vivo settings (63, 87, 92-94) . This apoptosis induction by PEITC was
characterized by G2-M cell cycle arrest, inhibition of the anti-apoptotic proteins, Bcl-xL,
Bcl-2 and Mcl1 and caspases 8 and 9 cleavage in prostate cancer and leukemia cells (95). Mi
et al., identified tubulin as an important binding target of PEITC in A549 lung cancer cells
(96). This study demonstrated that the covalent binding of PEITC and other isothiocyanates
to the tubulin proteins leads to disruption of microtubule polymerization, cell cycle arrest,
down regulation of cyclins A, D and E and cell death (96, 97). Interestingly, apoptosis
initiation in HT-29 colon cancer cells by PEITC was dependent upon activation of the MAP
kinase, JNK. Consequently SP600125, an anthrapyrazolone inhibitor of JNK suppressed
apoptosis by PEITC (98).
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Figure 1.4: Structure of PEITC
Chemical formula: C9H9NS
Molecular weight: 163.24
Reprinted with permission from (99): Moon YJ, Brazeau DA, Morris ME. Dietary phenethyl
isothiocyanate alters gene expression in human breast cancer cells. Evidence-based
complementary and alternative medicine : 2011.
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PEITC mediated cytotoxicity in cancer cells was unique because of two observations:
(a) PEITC treatment in cells led to excessive reactive oxygen species (ROS) generation (63,
64, 94, 100-102). Recent studies have attributed this ROS production to two mechanisms –
glutathione depletion and inhibition of oxidative phosphorylation by PEITC. This ROS stress
was of functional significance and correlated with cell death in cancer cells. In addition, the
ROS induction by PEITC was instrumental in ameliorating drug resistance to clinically used
anticancer agents such as Gleevec, Vorinostat and Fludarabine in leukemia cells.
(b) The cell death induced by PEITC was limited towards malignant cells with little
cytotoxicity against normal cells (63, 64, 94, 103). Previous studies in our lab demonstrated
that this preferential PEITC-cytotoxicity was due to altered redox biology between normal
and cancer cells. Mitochondrial respiration deficient Rho-0 prostate cancer cells were also
resistant to the antiproliferative activity of PEITC suggesting that the therapeutic selectivity
of PEITC relies on mitochondria dependent mechanisms.
My PhD dissertation was focused on investigating the mechanisms of cytotoxicity
and therapeutic selectivity of PEITC against melanoma cells. I had been particularly
interested in examining if the redox differences between normal melanocytes and melanoma
cells could be used as a therapeutic basis to preferentially eliminate melanoma cells. Further,
mechanistic studies were undertaken to characterize the utility of PEITC to combat drug
resistance to clinically used melanoma drugs such as Temozolomide and Carmustine. The
results from my study on the anticancer activity of PEITC in melanoma have been discussed
in chapter 4.
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1.3 Research hypothesis and specific aims
The central research hypothesis for my PhD dissertation was - alterations in reactive
oxygen species (ROS) and lipid metabolism in melanoma cells, as compared to normal
melanocytes, may serve as a biochemical basis to preferentially kill malignant melanoma
cells using proper pharmacological agents such as OSW-1 and PEITC.
To address this hypothesis I identified the following two specific aims:
1. To investigate altered lipid metabolism as the biological basis to preferentially
eliminate melanoma cells using OSW-1.
2. To investigate ROS stress as a biochemical basis to selectively kill melanoma cells
using PEITC.
In order to effectively achieve both of these specific aims, each specific aim was
further divided into three sub aims. Experiments were designed to investigate each of these
sub aims. The specific aims and the corresponding sub aims have been listed below:
Specific aim 1: To investigate altered lipid metabolism as the biological basis to
preferentially eliminate melanoma cells using OSW-1.
a) To determine the effect of OSW-1 on ganglioside expression in melanoma cells.
b) To investigate the effect of OSW-1 on mitochondrial functionality in melanomas.
c) To characterize the molecular mechanisms underlying the therapeutic selectivity of
OSW-1 towards melanoma cells.
Specific aim 2: To investigate ROS stress as a biochemical basis to selectively kill melanoma
cells using PEITC.
a) To determine the antiproliferative effect of PEITC in melanoma cells.
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b) To characterize the underlying redox mechanisms that are pivotal to PEITC’s activity
in melanoma cells.
c) To elucidate therapeutic strategies to combat drug resistance in melanoma using
PEITC.
The following chapters describe the project design, results obtained, key conclusions
from my study and the future directions of my research.
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Chapter 2: Materials and Methods
2.1 Chemicals and reagents
The compound OSW-1 was kindly provided by Dr. Zhendong Jin from the University of
Iowa (Iowa City, Iowa). Β-Phenylethyl Isothiocyanate (PEITC) was purchased from SigmaAldrich (St. Louis, MO). The original stock solutions of OSW-1 and PEITC were prepared in
DMSO. For all experiments, OSW-1 and PEITC were diluted in the media at a concentration
of 0.1% or less of the solvent DMSO. The fluorescent dyes Rhodamine 123, calcium green-1
AM, mitotracker red CMXRos, Dihydroethidium and mitoSOX red mitochondrial
superoxide indicator were purchased from Life Technologies (Grand Island, NY). Annexin
V-FITC and the 10X binding buffer were purchased from BD Pharmingen (San Jose, CA). 3(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide (MTT), Giemsa stain, 4,4'diisothiocyano stilbene-2,2'-disulfonic acid (DIDS), Cyclosporin A (CsA), 3-Methyladenine
(3-MA), Chloroquine (CQ), Triptolide, and propidium iodide (PI) were purchased from
Sigma-Aldrich (St. Louis, MO).
2.2 Cell culture
The melanoma cell lines A375P, A2058, WM115 were purchased from American Type
Culture Collection (ATCC, Manassas, VA). A375SM, WM35, WM46, MEWO, MEL624,
SK-MEL-2, UCSD-354L, and Hs294T cell lines were purchased from the characterized cell
line core at University of Texas MD Anderson Cancer Center (Houston, TX); these cell lines
were validated at the core facility by STR finger printing. The normal human epithelial
melanocytes (NHEM) were purchased from Promocell (Heidelberg, Germany). NHEM cells
were cultured in M254CF medium (Life Technologies, Long Island, NY) supplemented with
PMA-free human melanocyte growth supplement-2 (Life Technologies, Long Island, NY)
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and were grown at 37 ºC, 5% CO2 in a cell culture incubator. MEF VDAC1-/- cells were a
generous gift of Dr. William Craigen (Baylor College of Medicine, Houston, TX) and were
cultured in DMEM medium supplemented with 10% heat inactivated fetal bovine serum
(FBS) and sodium pyruvate. A375P, A375SM, A2058 cells cultured in DMEM medium
(Mediatech, Manassas, VA) supplemented with 10% heat inactivated FBS were grown in a
cell culture incubator with 5% CO2 at 37 ºC in humidified air. WM35, WM46, WM115,
MEWO, MEL624, SK-MEL-2, UCSD-354L, and Hs294T cells were grown in RPMI 1640
medium (Mediatech, Manassas, VA) supplemented with 10% heat inactivated FBS in a cell
culture incubator with 5% CO2 at 37 ºC in humidified air.
2.3 MTT assay for cell viability
Cell growth inhibition induced by OSW-1 and PEITC was assayed by performing the MTT
assay as previously described (104). Briefly, melanoma cells, seeded in 96-well plates, were
treated with log-scale serial diluted concentrations of OSW-1 and PEITC. After 72 h of
incubation, 50 µl of MTT reagent per well was added for 4h. The cell media was then
aspirated, formazan precipitates dissolved in DMSO and absorbance at 570 nm was
measured in a Multiskan MK3 microplate-reader (Thermo Labsystem, Franklin, MA). The
50% inhibitory concentration (IC50) values were then computed using GraphPad Prism
(GraphPad Software, Inc. La Jolla, CA).
2.4 Colony formation assay
The colony formation assay was performed as described previously (105). Briefly,
melanoma cells (5000 cells/well) were seeded in a 6-well plate and treated with varying
concentrations of inhibitors for 2 weeks. The cells were then fixed with methanol/acetic acid
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(10:1) solution, and stained with Giemsa (Sigma-Aldrich, St. Louis, MO). The cells were
photographed and the colonies counted.
2.5 Mitochondrial membrane potential measurement by Rhodamine 123 staining
Rhodamine 123 assay was used to monitor the integrity of mitochondria following drug
treatments as previously described (106, 107). Melanoma cells or normal melanocytes were
treated with OSW-1, PEITC or other inhibitors for the indicated time points and then
incubated in 0.5 µM rhodamine 123 dye during the last 1 h of drug treatment. The cells were
then dissociated, washed twice with PBS and ∆Ψm measured using a BD Biosciences
FACSCalibur flow cytometer (Mountain View, CA). Data analysis was performed using
FlowJo (TreeStar Inc., Ashland, OR).
2.6 Annexin-V/PI analysis for apoptosis
Cell death by apoptosis/necrosis was measured by flow cytometric analysis of cells dual
stained for annexin V-FITC and propidium iodide (108). Briefly, melanoma cells grown in 6well plates were treated with inhibitors for the indicated time points, harvested and stained
with annexin V-FITC for 15 minutes, washed and then stained for propidium iodide. Cell
death was measured using a BD Biosciences FACSCalibur flow cytometer (Mountain View,
CA) and the results were analyzed using the FlowJo software (TreeStar Inc., Ashland, OR).
2.7 Electron microscopy
The electron microscopy experiment was performed at the high resolution electron
microscopy facility (core grant CA16672) at the MD Anderson cancer center, as per the
core’s prescribed protocol. Briefly, melanoma cell samples were fixed with a solution
containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3,
for 1 h. After fixation, the samples were washed and treated with 0.1% Millipore-filtered
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cacodylate buffered tannic acid, post-fixed with 1% buffered osmium tetroxide for 30 min,
and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated
in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The
samples were polymerized in a 70 ºC oven for 2 days. Ultrathin sections were cut in a Leica
Ultracut microtome (Leica, Deerfield, IL), stained with uranyl acetate and lead citrate in a
Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL,
USA, Inc., Peabody, MA) at an accelerating voltage of 80 kV. Digital images were obtained
using the AMT Imaging System (Advanced Microscopy Techniques Corp, Danvers, MA).
2.8 Immunoblotting
Immunoblotting was performed to assess protein expression in drug treated and control cell
lysates (109). Proteins were separated on 10-15% SDS-PAGE gels, transferred onto
nitrocellulose membranes and immunoblotted using the following commercially available
antibodies: β-actin (Calbiochem, San Diego, CA), LC3B (Novus Biologicals, Littleton, CO),
VDAC1 (Abcam, Cambridge, MA), phosphorylated and total ERK1/2, and Caveolin (Cell
Signaling Technology, Inc., Danvers, MA). Membranes were then incubated with
appropriate horseradish peroxidase conjugated secondary antibodies and the signal visualized
using supersignal enhanced chemiluminescence kit (Thermo Scientific, Rockford, IL).
2.9 Detection of ganglioside expression by flow cytometry
Assessment of ganglioside expression changes following drug treatment was performed by
flow cytometry as previously reported (24). Melanoma cells were treated with OSW-1 or
other inhibitors for the indicated time durations, harvested, washed twice in PBS and stained
for 30 min, 4 ºC, with the following commercially available antibodies: PE-anti human
ganglioside GD2 (Biolegend, San Diego, CA), disialoganglioside GD3 (BD Biosciences, San
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Jose, CA) and anti GM3 (NeuAc) antibody (Cosmo Bio USA, Inc., Carlsbad, CA). Samples
stained with PE-conjugated GD2 antibody were washed and directly assayed using the BD
Biosciences FACSCalibur flow cytometer (Mountain View, CA). Samples probed with GM3
and GD3 antibodies were washed, stained with a FITC-conjugated secondary antibody for
another 30 min, 4 ºC and the GM3/GD3 expression was measured by flow cytometry. All
data analysis was performed using FlowJo (TreeStar Inc., Ashland, OR).
2.10 Lipid raft / ganglioside enriched microdomain (GEM) isolation
The lipid raft fractions were prepared using a detergent extraction protocol described by
Mitsuda et al (110). Two T-175 flasks of 80-90% melanoma cells were used for each
preparation. Briefly, cells were harvested, washed twice in ice-cold PBS and suspended in 1
mL of TNE buffer (1% Triton X-100, 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EGTA). The cells were then dounce homogenized 24 times, mixed with equal volume of
80% sucrose and placed at the bottom of ultra-clear centrifuge tubes (Beckman Coulter,
Brea, CA). 2 mL of 30% sucrose solution in TNE buffer without Triton X-100 and 1 mL of
5% sucrose solution in TNE buffer without Triton X-100 were carefully laid on top of the
preparation. The samples were then centrifuged at 105,000 × g in a Beckman Coulter Optima
XPN-100 ultracentrifuge (Brea, CA) for 16 h at 4°C. From the top of the gradient, 9
fractions of 0.5 mL sample were collected and assayed by SDS-PAGE or dot blot.
2.11 Real time RT-PCR
To analyze mRNA expression of GD3S, GD2S, FASN and HMGCR, real time RT-PCR was
performed as previously described (111). Briefly, total RNA was extracted from melanoma
cells using the RNeasy mini kit (Qiagen, Valencia, CA). 2 µg of RNA was subjected to
reverse transcription with random hexamer primers utilizing the revertaid first strand cDNA
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synthesis kit (Thermo Scientific, Pittsburg, PA). Real time PCR was performed on an
Applied Biosystems Viia7 machine using SYBR green with the following cDNA primers:
FASN

forward:

5’

–

CGCTCGGCATGGCTATCT-3’;

FASN

reverse:

5’-

CTCGTTGAAGAACGCATCCA-3’; HMGCR forward: 5’-GGCCCAGTTGTGCGTCTT3’;

HMGCR

reverse:

5’-CGAGCCAGGCTTTCACTTCT-3’;

GD3S

forward:

5’-

TGTGGTCCAGAAAGACATTTGTGGACA-3’;

GD3S

reverse:

5’-

TGGAGTGAGGTATCTTCACATGGGTCC-3’;

GD2S

forward:

5’-

GACAAGCCAGAGCGCGTTA-3’

GD2S

reverse:

5’-

and

TACTTGAGACACGGCCAGGTT-3’. All experiments were performed with three
biological replicates and three technical replicates and the results have been reported as the
mean of the biological replicates plus or minus standard error.
2.12 Immunofluorescence staining and confocal microscopy
Immunofluorescence staining and confocal microscopic analysis were performed based on
previously reported protocols (10, 112). Melanoma cells were cultured on sterilized glass
coverslips, treated with OSW-1 and incubated in 50 nM mitotracker red for 25 min. Cells
were washed twice with PBS, fixed with 3.7% paraformaldehyde in medium at 37 °C for
10 min, permeabilized using 0.3% Triton X-100 for 10 minutes, washed and then blocked
with 4% FBS for 1 h. The samples were incubated overnight with the disialoganglioside GD3
(BD Biosciences, San Jose, CA) and/ or VDAC1 (Proteintech, Chicago, IL) antibodies,
washed and incubated in FITC- and rhodamine red X-conjugated secondary antibodies
(Jackson Immunoresearch Laboratories, Inc., West grove, PA) for 1 h. The samples were
then washed and mounted onto glass slides using the Ultracruz mounting medium (Santa
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Cruz Biotechnology, Dallas, TX). Images were taken by NIKON Eclipse TE2000 confocal
microscope and analyzed using the Nikon EZ-C1 software.
2.13 Cytosolic calcium detection
Cytosolic calcium levels were measured as previously described (109). Briefly, melanoma
cells were treated with OSW-1 or other inhibitors for the indicated time durations, harvested,
washed twice in PBS and stained with calcium green fluorescent dye for 30 min at 4 ºC.
Cytosolic calcium levels were detected in the FL-1 channel of the BD Biosciences
FACSCalibur flow cytometer (Mountain View, CA).
2.14 Detection of cellular free radical expression by staining with the fluorescent dyes
DCFDA, DAF-FM, Dihyroethidium and mitoSOX mitochondrial superoxide indicator
Flow cytometric measurements using the CM-H2-DCFDA, DAF-FM or Dihydroethidium
fluorescent probes was performed to detect free radical levels in cells (63, 113). Briefly,
melanoma cells were treated with OSW-1, PEITC or other inhibitors for the indicated time
points and then incubated in 1 µM mitosox red or CM-H2-DCFDA or DAF-FM or
Dihydroethidium during the last 1 h of drug treatment. The cells were then dissociated,
washed twice with PBS and the free radical expression levels were measured using a BD
Biosciences FACSCalibur flow cytometer (Mountain View, CA). Data analysis was
performed using FlowJo (TreeStar Inc., Ashland, OR).
2.15 siRNA transfection
Tranfection of VDAC1 and control siRNAs was performed as previously reported (114).
Briefly, A375SM melanoma cells were plated in a 6-well plate and cultured until 50%
confluency, at which point, they were transfected with 50 nM silencer select siVDAC1 (ID:
s14769) or the negative control siRNA (Life Technologies, Long Island, NY) by the
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Lipofectamine RNAiMAX reagent (Life Technologies, Long Island, NY). Western blot was
performed to determine VDAC1 expression 48 h post-transfection.
2.16 Glutathione assay
A glutathione assay kit (Cayman Chemicals, Ann Arbor, MI) was used to detect cellular
glutathione levels (63, 94, 113). Cell extracts were obtained by sonication (power setting - 4,
10 s 3X) and deproteination as per the manufacturer’s guidelines. The reaction product of
glutathionylated 5, 5’-dithiobis-(2-nitrobenzoic acid) was detected spectrophotometrically
using the Multiskan MK3 microplate-reader (Thermo Labsystem, Franklin, MA) at 450 nm.
A standard curve for glutathione was generated and the glutathione concentration in each
sample was calculated. The Bicinchoninic Acid (BCA) assay was performed to determine
sample protein concentration and to normalize the glutathione concentration across samples.
GraphPad Prism (GraphPad Software, Inc. La Jolla, CA) was used to perform all statistical
analysis.
2.17 Reverse phase protein array (RPPA) analysis
The RPPA experiments were performed at the functional proteomics reverse phase protein
array core (NCI # CA16672) at the MD Anderson cancer center, following the core’s
experimental protocols (115). Briefly, melanoma cells lysates were extracted in the following
lysis buffer: 1% Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM
EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, containing
freshly added protease and phosphatase inhibitors. Cellular proteins were denatured by 1%
SDS (with beta-mercaptoethanol) and diluted in five 2-fold serial dilutions in dilution buffer
(lysis buffer containing 1% SDS). Serial diluted lysates were arrayed on nitrocellulose-coated
slides (Grace Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Sample slides were
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probed with 217 primary antibodies and the corresponding biotin-conjugated secondary
antibody. The signal obtained was amplified using a Dako Cytomation–catalyzed system
(Dako) and visualized by DAB colorimetric reaction. The slides were scanned, analyzed, and
quantified using a customerized-software Microvigene (VigeneTech Inc.) to generate spot
intensity. Each dilution curve was fitted with a logistic model (“Supercurve Fitting”
developed by the Department of Bioinformatics and Computational Biology in MD
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). The protein
concentration of each set of slides was then normalized by median polish, which was
corrected across samples by the linear expression values using the median expression levels
of all antibody experiments to calculate a loading correction factor for each sample. Heat
maps were generated in Cluster 3.0 (http://www.eisenlab.org/eisen/) as a hierarchical cluster
using Pearson Correlation and a center metric. The resulting heatmap was visualized in
Treeview (http://www.eisenlab.org/eisen/).
2.18 Statistical analysis
Statistical analysis was computed using GraphPad Prism version 6 (La Jolla, CA). Data were
graphed as mean ± standard error (SEM) for experiments performed in triplicates unless
noted differently. A standard student’s two tailed t-test was performed to determine
statistically significant difference between samples at a 95% confidence interval. In all
cases, **** denotes p < 0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p<
0.05.
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Chapter 3: The anti-tumor agent, OSW-1, effectively eliminates melanoma cells
through ganglioside GD3 and mitochondrial VDAC1 dependent mechanisms
3.1 Introduction
The natural product OSW-1 is a highly potent anticancer agent. Previous studies both
from our lab and others demonstrated that OSW-1 inhibited cancer cell viability at subnanomolar concentrations with minimal toxicity towards normal cells (67, 81). Further, it
was effective in eliminating various cancer cells including leukemia, glioblastoma and
pancreatic cancers that were resistant to other clinically used agents such as taxol, adriamycin
and fludarabine (59, 67).
Previous research efforts from our lab revealed that OSW-1 inhibited the sodiumcalcium exchanger 1 (NCX1) on the cell membrane of HL-60 leukemia cells, leading to
cytosolic calcium elevations, caspase 3 activation and mitochondria dependent apoptosis
(58). However, the mechanisms of OSW-1 induced cytotoxicity in solid tumors still remain
to be elucidated. Recent studies demonstrated that steroidal compounds such as Estradiol and
Triptolide inhibited ganglioside 3 synthase (GD3S) expression in cancer cells, thus causing
cell death (56, 116). Further, a strong interaction between OSW-1 and GM3 gangliosides in
melanoma cells has been noted (83).
In this study, we investigated the effect of OSW-1 on ganglioside expression in melanoma.
Effect of OSW-1 on the ganglioside synthesis regulatory enzyme, GD3 synthase (GD3S) was
also examined. Our results indicate that OSW-1 suppresses GD3 synthase gene expression in
melanoma cells, leading to inhibition of gangliosides, GD3, GD2 and subsequent cell death
by autophagy. Further, OSW-1 promoted interaction between GD3 and mitochondrial
VDAC1 in melanoma cells. Significantly, OSW-1 upregulated VDAC1 expression in
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melanoma, leading to loss of calcium homeostasis and cell death. These OSW-1 induced
alterations in ganglioside and VDAC1 expression play a critical role in mediating the
selectivity of OSW-1 to malignant melanoma cells.
3.2 Results
3.2.1 Cytotoxic effect of OSW-1 in melanoma
Previous findings, both from our lab and others, demonstrate that OSW-1 inhibits cell
viability in multiple tumor cell lines including Leukemia, brain, colorectal, hepatic and
pancreatic cancers at nanomolar concentrations (59, 69). To investigate the effect of OSW-1
on melanoma cell proliferation, we first performed an MTT assay with multiple melanoma
cell lines. As illustrated in figure 3.1, OSW-1 is highly potent in inhibiting melanoma cell
growth with an average half-maximal inhibitory concentration (IC50) of 0.178 nM. A
subsequent colony formation assay of WM35 cells treated with increasing concentrations of
OSW-1 indicated that only 36% of cells formed colonies at a concentration of 0.1 nM, with a
complete inhibition of colony formation at higher concentrations (figure 3.2 A, B). Because
many of the metastatic melanoma cells did not form colonies on 6-well plates, we adapted
the MTT assay for long term (figure 3.2 C, D). Melanoma cells were incubated in log-scale
increasing concentrations of OSW-1 for 8 days. MTT assay was performed in these cells to
elucidate the effect of OSW-1 on cell proliferation (figure 3.2 C). As indicated in figure 3.2
D, OSW-1 inhibited melanoma cell growth at sub-nanomolar concentrations with an average
IC50 of 0.058 nM.
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Figure 3.1:
A
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0.178 ± 0.043
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0.156 ± 0.024
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0.097 ± 0.001

MEWO

0.343 ± 0.068

Figure 3.1: Effect of OSW-1 on melanoma cell viability
(A) Melanoma cells were treated with log-scale serial diluted concentrations of OSW-1 for
72 h, and the antiproliferative effect was determined by performing the MTT assay. The cell
viability curves were plotted. Each data point represents mean ± SEM of three independent
measurements. (B) The 50% cell inhibitory concentration (IC50) ± SEM for each cell line is
indicated.
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Figure 3.2: OSW-1 inhibits colony formation in melanoma cells.
(A) and (B) WM35 cells treated with 0.1, 0.3 and 1 nM OSW-1 for 2 weeks were fixed,
stained with Giemsa and the number of colonies formed were counted. **** denotes p <
0.0001. (C) Melanoma cells were treated with log-scale serial diluted concentrations of
OSW-1 for 8 days, and the antiproliferative effect of OSW-1 was determined by performing
the MTT assay. The cell viability curves were plotted. Each data point represents mean ±
SEM of three independent measurements. (D) The 50% cell inhibitory concentration (IC50)
of each cell line in the long-term MTT assay is indicated.
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Figure 3.3:
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Figure 3.3: Effect of OSW-1 on mitochondrial membrane potential (∆Ψm) in melanoma
cells.
Melanoma cells were treated with either DMSO control or 1 nM OSW-1 for 72 h and the
effect of OSW-1 on mitochondrial membrane potential was determined by rhodamine 123
staining and flow cytometric analysis. OSW-1 induced collapse of membrane potential in
melanoma cells with an average DMSO vs. OSW-1 p-value = 0.007. **** denotes p <
0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05.
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Mitochondrial dysfunction has been implicated in cell death signaling in cells.
Maintenance of proper mitochondrial membrane potential (∆Ψm) is required for cellular
homeostasis and normal functioning of cells as it drives ATP synthesis and oxidative
phosphorylation (117). However, an acute induction of mitochondrial membrane
permeabilization (MMP) due to calcium overload, oxidative stress, inhibitors such as
etoposide, arsenite, lonidamine etc. can lead to cell death (118-122). Hence we sought to
investigate the effect of OSW-1 on mitochondrial transmembrane potential (∆Ψm) across a
panel of eleven melanoma cell lines (figure 3.3). OSW-1 caused an average decrease in
mitochondrial membrane potential in melanoma cells by 48%, as compared to the DMSO
treated control cells (control vs. OSW-1, p-value = 0.007, n = 11). Interestingly, SK-MEL-2
cells, which have a slightly higher IC50 (0.421 nM, figure 3.1 B) compared to other
melanoma cells, also exhibited decreased sensitivity to OSW-1 in the mitochondrial
membrane potential measurement assay, thus pointing towards the heterogeneity of drug
response to OSW-1 in melanomas.
3.2.2 OSW-1 triggered cell death in melanoma is associated with autophagy
Autophagy is an evolutionarily conserved lysosomal degradation pathway that is
essential for cellular homeostasis and response to stress conditions (123, 124). Previous
studies have classified autophagy as a non-apoptotic cell death characterized by enhanced
autophagic flux and accumulation of autophagic vacuoles in cells (125, 126). Transmission
electron microscopy results showed formation of numerous autophagic vacuoles in WM35
cells treated with OSW-1 (figure 3.4 A). This autophagic vacuole formation increased with
time with about a 9- and 21-fold increase in the observed number of autophagic vacuole per
cell at 24 h and 48 h of 1 nM OSW-1 treatment (figure 3.4 B). The autophagosome37

associated lipidated form of LC3B (LC3B-II) can be differentiated from the cytosolic free
isoform (LC3B-I) by immunoblotting (127). Consistent with the morphological findings, a
time dependent increased expression of the lipidated LC3B (LC3B-II) isoform was observed
in cells treated with OSW-1 (figure 3.5).
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Figure 3.4:
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OSW-1 48 h

B

**
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Figure 3.4: OSW-1 promotes autophagic vacuole formation in melanoma cells.
(A) Transmission electron microscopy images of WM35 cells treated with 1 nM OSW-1 for
24 h and 48 h. The black arrows indicate the autophagic vacuole formation induced by OSW1. (B) The number of autophagic vacuoles formed per cells for each samples were counted
and the mean ± SEM of three independent measurements are plotted as bar graphs. **
denotes p < 0.01.
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Figure 3.5:

LC3B-I
LC3B-II
β-Actin

Figure 3.5: Effect of OSW-1 on the autophagy marker, LC3B expression.
WM35 cells were treated with 1 nM OSW-1 for 12, 24 and 48 h and immunoblotting was
performed to examine lipidation of the autophagy marker protein LC3B.
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Figure 3.6:
A

B

**

OSW
Figure 3.6: Autophagy induction is crucial to cell death induction by OSW-1.
(A) WT and Atg5-/- MEF cells were treated with varying concentrations of OSW-1
OSW for 72 h
and the cytotoxic effect was determined by the MTT assay, as described in materials and
methods. Percent cell survival
rvival corresponding to each OSW
OSW-1
1 concentration was plotted. (B)
WM35 cells preincubated with 1mM 33-methyl
methyl adenine for 1 h were treated 1nM OSW-1
OSW for
48 h. Effect of OSW-1 ± 3-MA
MA combination on cell viability was evaluated by annexin-V/PI
annexin
analysis and is represented as bar graphs normalized to the DMSO control. ** denotes p <
0.01.
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The autophagy related protein 5, Atg5, is an essential autophagy protein, which
conjugates with Atg12 to form a multimeric structure that is crucial for autophagosome
formation (128, 129). Hence, we employed Atg5 knock out (Atg5-/-) MEF cells to
characterize the role of autophagy in mediating the cell inhibitory effect of OSW-1. MTT
results from WT and Atg5-/- MEF cells treated with log-scale incremental concentrations of
OSW-1 for 72 h demonstrated that the Atg5-/- cells exhibited decreased sensitivity to OSW-1
(figure 3.6 A). 1 nM OSW-1 effectively inhibited cell viability by approximately 80% in
MEF WT cells while an approximate 75% of MEF Atg5-/- cells were still viable at this
concentration. Nevertheless, higher concentrations of OSW-1 killed both MEF WT and
Atg5-/- cells. In complementation to this observation, the autophagy inhibitor, 3-Methyl
Adenine (3-MA), partially rescued WM35 cells from the cytotoxic effect of OSW-1 (130,
131). As shown in figure 3.6 B, OSW-1 treatment for 48 h abolished cell survival to 30%.
However, combination of OSW-1 with 3-MA reversed cell survival to 60.76%. These
findings not only delineate the significance of autophagy in OSW-1 induced elimination of
melanoma cells, but also allude to the fact that there might also be simultaneous alternate cell
death mechanisms facilitating OSW-1’s activity.
Interestingly, combination of OSW-1 with the lysosomotrophic agent Chloroquine led
to rapid apoptotic cell death. Chloroquine inhibits late phase autophagy by preventing the
fusion of the autophagosomes to lysosomes (132). Because of this mechanism of action,
chloroquine has found utility in sensitizing multiple cancer cells including hepatocellular and
cervical cancers to radiation and drugs like cisplatin and oxaliplatin (133, 134). Combination
of OSW-1 with chloroquine produced approximately 48% (normalized to control) increased
cell death in WM35 cells as compared to OSW-1 treatment alone (figure 3.7 A). To evaluate
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the type of drug interaction, we performed combination index (CI) analysis of different
combination regimens of OSW-1 (0.1, 0.3 and 1 nM, 48 h) and chloroquine (5, 10 and 20
µM, 48 h) in melanoma cells (135, 136). As described in figure 3.7 B, the combination
regimen between OSW-1 and chloroquine was synergistic (CI <1) for seven of the nine
combination treatments with 1 nM OSW-1 and 5 µM chloroquine showing the strongest
effect (CI = 0.111). Interestingly, an antagonistic combination effect (CI >1) was observed
on combining 20 µM chloroquine with 1 nM OSW-1 in WM35 cells.
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Figure 3.7:
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Figure 3.7: Cytotoxic effect of OSW-1 ± Chloroquine drug combination in melanoma
cells.
(A) 1 nM OSW-1 was added to WM35 cells pretreated with 10 µM chloroquine for 20 min.
After 72 h incubation, cell viability was determined by annexin v/PI staining and flow
cytometric analysis. The percentage of viable cells (negative for annexin V and PI) is
indicated. (B) WM35 cells were treated with the indicated concentrations of OSW-1 ± CQ
drug combination for 48 h and combination index analysis was performed using Compusyn
software. The combination index (CI) values were computed. The following quantitative
definitions, based on the Chou-Talalay theorem, were employed to define combination
effect: CI < 1 - synergism, CI = 1 - additive effect and CI > 1 - antagonism.
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Figure 3.8: Cytotoxic effect of OSW-1 ± Rapamycin drug combination in melanoma
cells.
(A) A375SM cells were treated with 1 nM OSW-1 ± 100 nM Rapamycin for 48 h and the
effect on mitochondrial membrane potential was determined by rhodamine 123 analysis. (B)
Bar graphs represent the mitochondrial membrane potential changes induced by A375SM
and WM35 cells treated with 1 nM OSW-1 ± 100 nM Rapamycin for 48 h. (C) Effect of 1
nM OSW-1 ± 100 nM Rapamycin 48 h treatment on the viability of A375SM and WM35
cells was determined by annexin-V/PI analysis and is represented as bar graphs. ** denotes p
< 0.01.
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The mammalian target of rapamycin (mTOR) serves as a central regulator of
autophagy by inhibiting phosphorylation of the autophagy proteins Atg13 and Unc51-like
kinase (ULK), and preventing autophagosome formation (137-139). The antibiotic,
Rapamycin inhibits mTOR thus acting as a potent autophagy inducer in multiple cell lines
(140, 141). In our study, we found that rapamycin ameliorated the cytotoxic effect of OSW-1
in melanoma cells (figure 3.8). A375SM and WM35 cells were co-treated with 1 nM OSW-1
and 100 nM rapamycin for 48 h and the effect on mitochondrial transmembrane potential
(∆Ψm) and cell death was assessed through flow cytometry by staning the cells with
rhodamine 123 (figure 3.8 A, B) and annexin-FITC/PI (figure 3.8 C). As illustrated in figure
3.8 A and B, rapamycin partially reversed the mitochondrial membrane permeabilization
induced by OSW-1. 1 nM OSW-1 caused a loss of membrane potential by 56.33% and
60.3% in A375SM and WM35 cells. However, rapamycin + OSW-1 treatment led to a
reversal of this effect to 16.2% and 34.07% in A375SM and WM35 cells. Similarly,
rapamycin also partially rescued A375SM and WM35 cells from the antiproliferation effect
of OSW-1 (figure 3.8 C). These drug combination (OSW ± chloroquine/rapamycin) results
elucidate the dual roles of autophagy in maintaining cellular homeostasis wherein though
autophagy might start-off as a cell protective mechanism, sustained autophagy mediated by
OSW-1 leads to melanoma cell killing.
3.2.3 Normal melanocytes are resistant to OSW-1 induced cytotoxicity
The promising antineoplastic effect of OSW-1 against melanoma cells led us to
examine the effect of this compound in normal melanocytes. As shown in figure 3.9, OSW1induced a time dependent loss of mitochondrial potential in A375SM melanoma cells, while
normal melanocytes were resistant to this effect of OSW-1. 1 nM OSW-1, 72 h treatment, did
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not trigger significant mitochondrial membrane potential loss in normal melanocytes (17.4%;
figure 3.9 A) compared to melanoma cells (n = 11, 52%; figure 3.3).

Figure 3.9:
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Figure 3.9: Effect of OSW-1 on mitochondrial membrane potential in normal
melanocytes vs. melanoma cells.
Mitochondrial membrane potential in normal melanocytes and A375SM cells treated with 1
nM OSW-1 for 48 h and 72 h was evaluated by rhodamine 123 staining as described in
materials and methods.
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Figure 3.10: Selective killing of melanoma cells by OSW-1.
(A) Melanoma cells and normal melanocytes were treated with 0.5, 1 and 2 nM OSW-1 for
72 h and the effect on cell viability was determined by annexin V/PI analysis. Each data
point represents the mean of three independent measurements. (B) Comparison of viability of
A375SM cells and normal melanocytes treated with 1 nM OSW-1 for indicated time
duration. Cell viability was determined by annexin V-FITC/PI staining. The numbers
indicate the percentage of viable cells (negative for annexin V and PI).
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We designed a follow-up time course experiment with 1 nM OSW-1 and performed
an annexin-V/PI staining assay to determine the effect of OSW-1 on cell death. Normal
melanocytes were resistant to the cytotoxic effect of OSW-1; 97.04% of normal melanocytes
were still viable after OSW-1 treatment for 96 h as compared to only 3.9% of A375SM
melanoma cells (figure 3.10 B). Figure 3.10 A represents the cell inhibitory effect of OSW-1
against multiple melanoma cell lines (n = 7) and normal melanocytes treated with increasing
concentrations of OSW-1 for 72 h. The scatter plot while delineating the heterogeneous
response of melanoma cells to OSW-1, also highlights the therapeutic selectivity of OSW-1
towards melanoma cells (1 nM OSW-1, average melanoma (n = 7) cell viability = 46.88%)
with limited toxicity to normal melanocytes (1 nM OSW-1, average cell viability = 93.30%).
3.2.4 OSW-1 inhibits ganglioside GD3/GD2 expression in melanoma cells
Recent studies by Kwon et al and Battula et al demonstrated that Triptolide, a
diterpenoid triepoxide, inhibits ganglioside GD3 and GD2 expression by repressing GD3
synthase (ST8Sia I) expression (24, 56). Since Triptolide bears structural similarity to OSW1, we hypothesized that OSW-1 would inhibit gangliosides GD3 and GD2 expression by
suppressing GD3 synthase (GD3S) expression. To test this hypothesis we assessed alterations
in ganglioside expression after OSW-1 treatment of melanoma cells (figure 3.11). Flow
cytometric analysis of WM35 and A375SM treated with OSW-1 and stained with ganglioside
antibodies revealed that OSW-1 caused a moderate decrease in ganglioside GD3 (figure 3.11
A, B) and a more striking inhibition of GD2 (figure 3.11 C, D). This inhibition of ganglioside
expression was time dependent, with GD2 inhibition starting as early as 3 h post OSW-1
treatment (figure 3.11 C, D). Figure 3.12 depicts the effect of OSW-1 on GD2 expression
against a panel of melanoma cell lines. On average, a 24 h OSW-1 treatment of melanoma
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cells reduced GD2 expression to 66.86% (DMSO vs. OSW-1, p-value = 0.0029). Further,
this GD3 and GD2 inhibition correlated with an accumulation of ganglioside GM3 (figure
3.11 E, F). A 24 h 1nM OSW-1 treatment led to an increased expression of ganglioside GM3
by 178.2% and 127.4% in A375SM and WM35 melanoma cells (figure 3.11 F).
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Figure 3.11: Effect of OSW-1 on ganglioside expression in melanoma.
(A), (C) and (E) A75SM cells treated with 1 nM OSW-1 for the indicated time points were
analyzed for ganglioside GD3, GD2 and GM3 expression by flow cytometry as described in
materials and methods. (B), (D) and (F) GD3, GD2 and GM3 ganglioside expression in
A375SM and WM35 cells treated with 1 nM OSW-1 for the indicated time points was
determined by flow cytometric measurements. Bar graphs represent mean ± SEM of percent
ganglioside (GD3/GD2/GM3) inhibition from three independent experimental measurements.
** denotes p < 0.01 and * denotes p< 0.05.
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Figure 3.12:
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Figure 3.12: Effect of OSW-1 on ganglioside GD2 expression in melanoma cells.
Melanoma cells were treated with either DMSO control or 1 nM OSW-1 for 24 h and the
effect of OSW-1 on ganglioside GD2 expression was quantified. Bar graphs represent mean
± SEM from three independent experiments. OSW-1 induced inhibited GD2 expression in
melanoma cells with an average DMSO vs. OSW-1 p-value = 0.0029. **** denotes p <
0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05.
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Figure 3.13:
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Figure 3.13: OSW-1 represses gene expression of GD3S, FASN and HMGCR enzymes.
Real time PCR was performed in A375SM cells treated with 1 nM OSW-1 for 12h and 24 h.
The effect of OSW-1 on the expression of GD3S, FASN and HMGCR genes was
determined. Each experiment was performed with three technical replicates. The bar graphs
represent the mean result from three biological replicates. **** denotes p < 0.0001, ***
denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05.
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Figure 3.14:

*

Figure 3.14: Effect of OSW-1 on GD2 Synthase gene expression.
Real time PCR was performed in A375SM cells treated with 1 nM OSW-1 for 12h and 24 h.
The effect of OSW-1 on the expression of GD2S gene was determined. * denotes p < 0.05.

58

Figure 3.15:
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Figure 3.15: Schematics of OSW-1 mediated modulation of ganglioside expression.
The model summarizes the effect of OSW-1 on ganglioside expression. OSW-1 suppresses
the expression of GD3 synthase gene leading to inhibition of GD3, GD2 and accumulation of
ganglioside GM3.
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Figure 3.16:
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Figure 3.16: Combination of OSW-1 with Triptolide partially reverses the OSW-1
induced mitochondrial membrane potential loss in melanoma.
A375SM cells were treated with 1nM OSW-1 ± 20 nM Triptolide for 48 h and the effect on
mitochondrial membrane potential was determined by rhodamine 123 analyses.
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As shown in figure 3.15, ganglioside GD3 is produced from its precursor GM3
through a reaction catalyzed the enzyme GD3 synthase. Results from real-time PCR,
performed to ascertain the effect of OSW-1 on GD3S mRNA expression, indicated that
OSW-1 represses GD3S gene expression in a time dependent fashion (figure 3.13).
Expression of GD2 synthase (GD2S) gene though initially suppressed by OSW-1, increased
after 24 h of OSW-1 treatment (figure 3.14). Interestingly, combination of Triptolide with
OSW-1 partially reversed the mitochondrial membrane collapse induced by OSW-1 (figure
3.16), suggesting that both OSW-1 and Triptolide elicit their antiproliferation activity
probably by acting on similar cellular targets. Yamauchi et al., (2011) demonstrated that
elevated GD3 levels correlated with increased expression of key lipogenic enzymes in
melanoma cell lines (10). Based on this, we hypothesized that inhibition of GD3 by OSW-1
would lead to suppressed expression of enzymes mediating the lipogenesis pathway.
Accordingly, 1 nM OSW-1 treatment for 24 h caused a 3.24- and 5.73-fold decrease in fatty
acid Synthase (FASN) and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR)
expression in melanoma cells (figure 3.13). Thus we conclude that OSW-1 suppresses GD3S
expression in melanoma leading to inhibition of gangliosides GD3 and GD2 and the
downstream lipogenic enzymes, FASN and HMGCR.
3.2.5 OSW-1 promotes interaction of ganglioside GD3 with VDAC1 in the mitochondria
Raft-like microdomains on the mitochondrial membrane are enriched with
gangliosides GD3 and GM3, and act as potential catalytic sites for autophagic and apoptotic
reactions (60, 142, 143). Activation of cell death receptor signaling via CD95/Fas or tumor
necrosis factor-α (TNF-α) promotes intracellular redistribution and vesicular transport of
ganglioside GD3 to mitochondria, wherein GD3 promotes apoptosis by acting on the
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mitochondrial transition pore and causing cytochrome c release (144-146). Garofalo et al.
(2005) also demonstrated that during CD95/Fas mediated apoptosis GD3 interacts with
voltage dependent anion channel 1 (VDAC1) and the fission protein hFis1 in the
mitochondrial lipid microdomains of lymphoblastoid CEM cells (143). Furthermore, prior
results from our lab suggest that OSW-1 has a mitochondrial mechanism of action (59).
Hence we investigated the effect of OSW-1 on mitochondrial targeting of GD3. To
characterize the distribution of GD3 and VDAC1 in the membrane microdomains, we
isolated lipid rafts fractions by performing a linear 5-80% sucrose gradient of the DMSO
control and OSW-1 treated A375SM cell lysates (figure 3.17). Majority of the lipid raft
resident protein caveolin-1 was recovered in fractions 2, 3 and 4. Ganglioside GD3 was also
concentrated in fractions 2, 3 (highest expression) and 4 of the DMSO control sample.
Nevertheless, OSW-1 administration promoted redistribution of GD3 expression to fractions
2, 3, 4, and 5. More significantly, OSW-1 stimulated elevated VDAC1 expression in the
corresponding fractions (2, 3, 4, and 5) whereas a diminished expression of VDAC1 was
observed in these caveolin enriched lipid raft fractions of the control sample. To confirm
these results, A375SM cells were treated with OSW-1 for 24 h and the cellular colocalization of VDAC1 and GD3 was examined by confocal microscopy. As shown in figure
3.18, OSW-1 potentiated increased co-localization of ganglioside GD3 with VDAC1in the
mitochondria, thus corroborating previous findings that cell death signaling triggered
intracellular redistribution and mitochondrial trafficking of GD3 (143, 145).
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Figure 3.17:
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Figure 3.17: Effect of OSW-1 on GD3 and VDAC1 co-expression in lipid rafts.
Glycosphingolipid enriched microdomain/lipid raft fractions from DMSO and 1 nM OSW-1
24 h treated A375SM samples were prepared and equal amounts of the fractions were
subjected to an immunoblot for VDAC1 and the lipid raft resident protein caveolin-1.
Simultaneously, a dot blot was performed to determine GD3 expression in the lipid raft
fractions. OSW-1 potentiates redistribution of GD3 and VDAC1 expression in lipid rafts.
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Figure 3.18:
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Figure 3.18: OSW-1 promotes co-localization of VDAC1 with ganglioside GD3.
A375SM cells were grown on coverslips and treated with 1 nM OSW-1 for 24 h. The cells
were stained with VDAC1 and GD3 antibodies as per the procedure described in materials
and methods and confocal microscopic images were taken.
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Figure 3.19:
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Figure 3.19: Correlation between OSW-1 induced mitochondrial membrane potential
loss and ganglioside GD2 inhibition.
The fold change in mitochondrial membrane potential induced by OSW-1 was plotted as a
function of fold change in GD2 expression. Linear regression analysis was performed and a
Pearson’s correlation coefficient of 0.7100 with a p value of 0.0144 was obtained.
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The relationship between inhibition of ganglioside GD3/GD2 expression and
sensitivity of melanoma cells to OSW-1 was evaluated quantitatively by plotting fold change
in mitochondrial membrane potential (∆Ψm) as a function of ganglioside GD2 expression
change upon OSW-1 treatment (figure 3.19). Our results indicate that there was a positive
correlation between these two factors (r = 0.7100, p = 0.0144), thus suggesting that
ganglioside inhibition sensitizes melanoma cells to the cytotoxic effect of OSW-1.
3.2.6 OSW-1 eliminates melanoma cells through mitochondrial VDAC1 dependent
mechanisms
OSW-1 stimulated increased interaction between GD3 and mitochondrial VDAC1
(figure 3.18). VDAC1 plays an important role in the transport of adenine nucelotides, Ca2+,
and other ions and metabolites across the mitochondria in addition to mediating apoptotic
and autophagic signaling in mitochondria (147-152). Therefore, we studied the role of
VDAC1 in OSW-1 induced cell death. Towards this end, we first examined melanoma cells
for VDAC1 expression after OSW-1 treatment. VDAC1 expression was markedly increased
by OSW-1 in A375SM and WM35 cells but was slightly decreased in normal melanocytes
which were resistant to OSW-1 (figure 3.20 A, B). On average, OSW-1 incubation for 36 h
triggered a 4.8- and 3.2-fold increase in VDAC1 expression in A375SM and WM35 cells
while a 1.7-fold decrease was observed in normal melanocytes (figure 3.20 C). Further, the
de novo protein synthesis inhibitor, cycloheximide reduced this VDAC1 elevation in
melanoma cells, indicating that OSW-1 caused a translational upregulation of VDAC1
(figure 3.21). Further, cycloheximide treatment for 2 h resulted in inhibition of 50% of
VDAC1 expression compared to the untreated control suggesting that the half-life of VDAC1
was around 2 h (figure 3.21). Significantly, Triptolide, which represses GD3 synthase, also
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led to VDAC1 induction by 1.4-fold in A375SM cells (figure 3.22). Collectively, these data
indicate that GD3S inhibition by OSW-1 may lead to VDAC1 activation and this VDAC1
increase positively correlates with cellular sensitivity to OSW-1 in melanoma cells.
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Figure 3.20:
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Figure 3.20: OSW-1 induces VDAC1 upregulation in melanoma cells.
Immunoblots of A375SM, WM35 and NHEM cells treated with 1 nM OSW-1 for 0.5, 12, 24
and 36 h (A) and 24 h only (B). (C) Densitometric measurement of the VDAC1 band
intensity relative to β-actin is shown. The bar graphs represent mean ± SEM of normalized
VDAC1 expression from three independent immunoblot assessments. * denotes p < 0.05.
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Figure 3.21: Effect of cycloheximide on OSW-1 induced VDAC1 upregulation in
melanoma cells.
A375SM cells were pre-incubated in 1 nM OSW-1 for 24 h, followed by 2 µM
cycloheximide treatments for 0.5, 1, 2, 4 and 8 h. Simultaneously A375SM cells were treated
with 2 µM cycloheximide as a single agent for 0.5, 1, 2, 4 and 8 h. Immunoblot was
performed to examine changes in VDAC1 expression.
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Figure 3.22:

T
DMSOP
L
VDAC1
1

1.44

β-Actin

Figure 3.22: Effect of Triptolide on VDAC1 expression in melanoma cells.
A375SM cells treated with 20 nM Triptolide for 24 h and VDAC1 protein expression was
detected by immunoblot analysis.
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Figure 3.23:
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Figure 3.23: Induction of mitochondrial superoxide release by OSW-1 in melanoma.
A375SM and WM35 cells treated with 1 nM OSW-1 for the indicated time points were
probed with the fluorescent mitochondrial superoxide indicator, mitosox red and the
mitochondrial superoxide release was determined by flow cytometric analysis. **** denotes
p < 0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05.
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Figure 3.24:
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Figure 3.24: OSW-1 induces cytosolic calcium elevation in melanoma cells.
A375SM and WM35 cells were treated with OSW-1 for the indicated time points and the
changes in cytosolic calcium levels were quantified using the calcium green fluorescent
probe. (A) A representative histogram of the calcium changes induced by OSW-1. (B) Bar
graph indicates the mean ± SEM of percent calcium increase in A375SM and WM35 cells
from three independent experiments. * denotes p < 0.05.
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Apart from VDAC1 induction, OSW-1 also stimulated mitochondrial superoxide
release (figure 3.23) and increase of cytosolic calcium (figure 3.24) in a time-dependent
fashion. The immunosuppressant cyclosporin A (CsA) inhibits cyclophilin D, a
mitochondrial matrix peptidyl-prolyl isomerase known to modulate opening of the
mitochondrial transition pore (153, 154). In addition, CsA, through pharmacological
inhibition of the serine/threonine phosphatase, calcineurin, promotes cell death in melanoma
and other solid tumors (155-157). Therefore it was conceivable to evaluate the effect of CsA
on OSW-1 mediated cytotoxicity in melanoma. Pre-incubation of WM35 cells with CsA
increased the antiproliferation effect of 0.3 nM OSW-1 from 22.0% to 73.3% (figure 3.25 A).
Similarly, combination of OSW-1 with CsA caused a 10.25-fold decrease in mitochondrial
membrane potential as compared to the DMSO control while 0.3 nM OSW-1 single agent
treatment caused a slight increase by 1.8 fold (figure 3.25 B). Interestingly, CsA+OSW-1
incubation for 24h promoted incremental VDAC1 expression in WM35 cells (figure 3.26 A).
This VDAC1 induction by CsA+OSW-1 combination was slightly higher than the effect of
OSW-1 as a single agent, while CsA by itself did not cause affect VDAC1. Further, preincubation of CsA with OSW-1 potentiated higher cytosolic calcium release when compared
to the effect of CsA/OSW-1 as a single agent (figure 3.26 B, C). The cytosolic Ca2+ levels in
WM35 cells treated with CsA+OSW-1 for 24 h increased to 229.5% while OSW-1 or CsA
alone caused Ca2+ elevation to 200.7% and 156.2% respectively (figure 3.26 C). These
results, together with our previous findings, demonstrate that the mitochondrial outer
membrane protein, VDAC1 and other mitochondria dependent mechanisms including
superoxide release and Ca2+ elevation play an important in leukemia cells executing the
anticancer activity of OSW-1 (58, 59).
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Figure 3.25:

A

96.5 %

91.4 %

DMSO

10 µM CsA

78.0 %

0.3 nM OSW-1

26.7 %

OSW-1 + CsA

B
CsA +
OSW-1
CsA
OSW-1
DMSO

Figure 3.25: Combination of OSW-1 with Cyclosporin A (CsA) causes elevated cell
death effect in melanoma cells.
(A) Melanoma cells treated with the indicated concentrations of OSW-1 and CsA for 48 h,
were analyzed for cell death by annexin V/PI staining. The numbers denote percent cell
viability (annexin V negative/PI negative) for each sample. (B) Mitochondrial membrane
potential loss in cells treated with 0.3 nM OSW-1 ± 10 µM CsA for 48 h was detected by
rhodamine 123 staining.
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Figure 3.26: Effect of OSW-1 and Cyclosporin A (CsA) drug combination on VDAC1
expression and calcium homeostasis.
(A) Immunoblot was performed in WM35 cells treated with 1 nM OSW-1 ± 2 µM CsA for
24 h. (B) and (C) Cytosolic calcium changes in A375SM and WM35 cells treated with 1 nM
OSW-1 ± 3 µM CsA for 24 h was determined. Figure (B) denotes a representative histogram
of the calcium changes induced by OSW-1 in A375SM cells.
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Figure 3.27:

A
OSW-1

OSW-1
DMSO 0.5

12 24

DMSO 0.5

36

12 24 36

p-ERK 1/2

A p-ERK 1/2
37
5S
ERK 1/2
M

W
M
35

ERK 1/2

β-

β-Actin

B

C
OSW-1 +
U0126

U0126

OSW-1
DMSO

Figure 3.27: OSW-1 treatment causes elevated expression of phosphorylated ERK1/2 in
melanoma.
(A) A375SM and WM35 cells were treated with 1 nM OSW-1 for the indicated time points
and immunoblot was performed for total and phosphorylated-ERK1/2 proteins. (B) and (C)
A375SM cells pre-incubated in 5 µM U0126 for 1 h were treated with 1 nM OSW-1 for 48 h.
Mitochondrial membrane potential and cell viability were determined by rhodamine 123 (B)
and annexin-V/PI analysis (C). Bar graphs represent the mean ± SEM measurements of three
individual experiments.

76

Tringali et al. identified that ganglioside GM3 accumulation in K562 cells drove cell
differentiation towards megakaryocytes and increased ERK1/2 phosphorylation through
protein kinase C dependent cell signaling (158). Recent reports also indicate a positive
correlation between GM3 accumulation and ERK1/2 activation in the brain astrocytes from a
sandhoff disease mouse model (159). Further, overexpression of GD3 synthase gene
inhibited PDGF-mediated ERK1/2 phosphorylation, thereby modulating cell proliferation
and cell cycle progression in vascular smooth muscle cells (VSMC) cells (160). OSW-1
induced a time dependent increase in phospho-ERK1/2 expression in A375SM and WM35
cells (figure 3.27 A). We hypothesized that if ERK1/2 activation was crucial to the antitumor
activity of OSW-1, then pre-incubation of melanoma cells with the MEK1/2 inhibitor, U0126
will rescue the cells from the cytotoxic effect of OSW-1. U0126 did not reverse the
mitochondrial membrane potential loss triggered by OSW-1 (figure 3.27 B). Moreover,
combination of OSW-1 with U0126 led to incremental inhibition of cell viability in
melanoma cells (figure 3.27 C). U0126+OSW-1 combination produced 31.70% increased
cell death in A375SM cells than OSW-1 single agent treatment (figure 3.27 C). Based on our
results, we conclude that ERK1/2 activation is not a critical mechanism in mediating OSW1’s anticancer effect, and is plausibly a downstream effect of the modulation of ganglioside
expression pattern by OSW-1.
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3.2.7 VDAC1 is a critical player in mediating the cytotoxic effect of OSW-1
To determine if VDAC1 induction is of functional significance to OSW-1 induced
cytotoxicity, we used VDAC1 knock out (VDAC1-/-) mouse embryonic fibroblast (MEF)
cells. We performed a72 h MTT assay with MEF WT and VDAC1-/- cells treated with log
scale serial diluted concentrations of OSW-1 (figure 3.28 A). MEF VDAC1-/- cells were
significantly resistant to OSW-1 with a half-maximal inhibitory concentration approximately
44 times higher than the WT MEF cells (figure 3.28 A). Likewise MEF VDAC1-/- cells were
resistant to the loss of mitochondrial membrane potential induced by OSW-1, whereas
incubation of MEF WT cells with 1, 3 and 10 nM OSW-1 incubation for 72 h resulted a
mitochondrial collapse to 41.85%, 29.50% and 16.85% respectively (figure 3.28 B).
To characterize the role of VDAC1 in melanoma cell sensitivity to OSW-1, we
performed siRNA mediated knock down of VDAC1 expression in A375SM cells (figure 3.29
A). As shown in figure 3.29 B and C, OSW-1 induced mitochondrial membrane potential
(∆Ψm) loss was substantially attenuated in siVDAC1 transfected A375SM cells. Further, a 48
h MTT assay in scrambled control and siVDAC1 transfected A375SM cells demonstrated
that the siVDAC1 cells were 4-times less sensitive to OSW-1 compared to the scrambled
control cells (figure 3.29 D). Interestingly the degree of resistance to OSW-1 observed in
siVDAC1 transfected A375SM cells was lower than the MEF VDAC1-/- cells ((figure 3.29
D, figure 3.28 A). This may be because of the transient nature of VDAC1 knockdown and
the need for A375SM cells to get acclimatized to this down regulation of VDAC1. Also, preincubation of A375SM cells with the VDAC inhibitor, DIDS, did not rescue the cells from
GD2 ganglioside inhibition triggered by OSW-1 (figure 3.30), thus indicating that VDAC1
does not have a regulatory function in the ganglioside expression change stimulated by
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OSW-1.
1. Collectively, our data strongly suggest that VDAC1 plays a crucial role in mediating
OSW-11 induced cytotoxicity in melanoma cells.
Figure 3.28:
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Figure 3.28: MEF VDAC1--/- cells are resistant to the cytotoxic effects of OSW-1.
OSW
(A) MEF WT and VDAC1-/-- cells were treated with log scale serial diluted concentrations of
OSW-11 for 72 h and the MTT assay was performed. IC50 values were determined. (B)
Mitochondrial membrane potential change induced by 72 h treatment of 1, 3 and 10 nM
OSW-11 in MEF WT and VDAC1
VDAC1-/- cells was determined by rhodamine 123 analysis. **
denotes p < 0.01 and * denotes p < 0.05.
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Figure
igure 3.29: Down regulation of VDAC1 in A375SM cells confers resistance to OSW-1.
OSW
(A) Immunoblot for VDAC1 in A375SM cells transfected with siVDAC1 and negative
control. (B) and (C) Mitochondrial membrane potential analysis of siVDAC1 and negative
control transfected A375SM cells treated with 1 nM OSW
OSW-1 for 48 h. (D) A375SM WT and
VDAC1-/- cells were treated with log scale serial diluted concentrations of OSW-1
OSW for 48 h
and the MTT assay was performed. IC50 values were determined. *** denotes p < 0.001.
0.001
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Figure 3.30:

Figure 3.30: Combination of OSW-1 with the VDAC1 inhibitor, DIDS, indicates that
VDAC1 does not regulate ganglioside expression.
A375SM cells were treated with 1 nM OSW-1 ± 200 µM DIDS for 24 h and ganglioside
GD2 expression was determined by flow cytometry.
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3.2.8 Characterization of the mechanisms underlying the therapeutic selectivity of
OSW-1
Therapeutic selectivity is a major concern while developing an anticancer agent. Our early
findings indicate that OSW-1 is highly selective towards melanoma cells with limited
toxicity in normal melanocytes (figure 3.9, 3.10). Hence we sought to delineate the
mechanisms causal this selectivity of OSW-1 for melanoma cells. Towards this end, we first
cultured WM35 cells in RPMI media supplemented with increasing concentrations of OSW1 for a period of 2-3 months to generate “OSW-1 resistant” WM35 cells (WM35R). An
aliquot of these cells were then returned back to RPMI media without OSW-1 (WM35 drug
withdrawn, WM35DW). These WM35DW cells continued to display the OSW-1 resistant
phenotype, despite being cultured in non-OSW-1 growth media, and thus represent the truly
OSW-1 resistant melanoma cells. A preliminary MTT assay indicated that WM35DW and
WM35R cells were about 680 and 332 times more resistant to OSW-1 than the parental
WM35 cells (figure 3.31). Henceforth, we used this WM35 vs. WM35DW vs. WM35R cell
model for our further study.
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Figure 3.31:

model.
Figure 3.31: The OSW-11 resistant WM35 cell model
Parental WM35 and the OSW
OSW-1
1 resistant WM35 R and WM35 DW melanoma cells were
treated with log scale serial diluted concentrations of OSW
OSW-1
1 for 72 h and the MTT assay
was performed to determine the antiproli
antiproliferative effect of OSW-1
1 in these cells.
cells The IC50
values for OSW-11 in each cell sample were determined.
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Figure 3.32:
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Figure 3.32: OSW-1 resistant WM35 DW cells have a decreased ganglioside GD3/GD2
expression profile compared to the parental WM35 melanoma cells.
The basal GD3 (A) and GD2 (B) expression in WM35, WM35 DW and WM35 R cells was
determined by flow cytometry as described in materials and methods. * denotes p < 0.05.

84

Figure 3.33:
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Figure 3.33: OSW-1 resistant WM35 DW cells have an altered free radical expression
profile compared to the parental WM35 melanoma cells.
(A) Basal mitochondrial superoxide levels were evaluated using the mitosox red fluorescent
indicator as described in materials and methods. Bar graphs represent mean ±SEM from three
independent experiments. (B) Basal level expression of reactive oxygen species, superoxides
and nitric oxide was determined by flow cytometric analysis of cells stained for DCFDA,
Dihydroethidium and DAF-FM fluorescent probes. * denotes p < 0.05.
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A comparison of the basal GD3 and GD2 ganglioside expression indicated that
WM35DW cells have a significantly decreased GD3 (p = 0.08) and GD2 (p = 0.02)
expression as compared to the parental WM35 cells (figure 3.32 A, B). But no significant
change in ganglioside GM3 expression between the two cell samples was observed. Further,
the basal mitochondrial superoxide levels were significantly reduced in WM35DW than the
parental WM35 cells (figure 3.33 A). This correlated with decreased expression of reactive
oxygen species, cytosolic superoxides and nitric oxide in the WM35DW vs. WM35 cells
(figure 3.33 B). Based on these results, we postulate that the basal ganglioside GD3/GD2
expression profile plays a critical role in governing the response of melanoma cells to the
antitumor effect of OSW-1.
To explore other potential markers of sensitivity to OSW-1, we performed reverse
phase protein array (RPPA) of 217 total- and phospho-proteins (figure 3.34). Of specific
interest to us were lipogenesis (figure 3.35 A, B), and mitochondria (figure 3.35 A, C)
signaling proteins, whose expression was statistically significantly different (p < 0.05)
between WM35 vs. WM35DW vs. WM35 R cells. RPPA analysis results demonstrate that
VDAC1 (porin), Bcl-2, Mcl-1, GSK3 and PKC-α expression was reduced in WM35DW and
WM35R compared to the parental WM35 cells (figure 3.35 A, C). However cyclophilin F
and phosphorylated NF-κB levels were higher in the resistant cells. Among the lipogenesis
proteins, fatty acid synthase (FASN) expression was significantly increased, while caveolin1, and focal adhesion kinase (FAK) expression was decreased in the WM35DW and WM35R
resistant cells than the parental WM35 cells (figure 3.35 A, B). Interestingly, expression
levels of cell survival and proliferation proteins like PI3K, Akt and phospho-MAPK and –
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MEK was lower in the resistant WM35DW and WM35R cells than the parental WM35 cells
(figure 3.34).
(Log 2)
Figure 3.34:
-0.8955

2.0779

Figure 3.34: Differential protein expression in WM35 vs. WM35 R vs. WM35 DW cells.
cells
Heat map generated based on the RPPA analysis of WM35 vs. WM35 DW vs. WM35 R cells for
the basal expression of the proteins indicated.
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Figure 3.35:
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Figure 3.35: Differential expression of lipogenesis and mitochondria signaling proteins
in WM35 vs. WM35 R vs. WM35 DW cells
cells.
RPPA analysis was performed in WM35 vs. WM35 DW vs. WM35 R cells. The expression
of proteins from the lipogensis (figures A, B) and mitochondrial signaling (figure A, C)
pathways that differed significantly in WM35 vs. WM35 DW vs. WM35 R cells is indicated
indicate
as a heat map and bar graphs.
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3.3 Discussion
In this study we demonstrated that OSW-1 effectively eliminates melanoma cells by
causing inhibition of gangliosides GD3/GD2 and upregulation of mitochondrial VDAC1
leading to autophagic cell death.
Burgett et al identified the lipid metabolism proteins, OSBP and ORP4L as cellular
binding targets of OSW-1(69). Prior findings from our lab demonstrated that OSW-1
functions by disrupting cellular calcium homeostasis through inhibition of the Na+/Ca2+
exchanger 1 (NCX1) leading to apoptotic cell death in leukemia cells (58). More recently,
Yamada et al., employed a fluorescent analog to investigate the cellular internalization and
localization of OSW-1 in HeLa cells (82). Microscopic imaging studies revealed that OSW-1
rapidly internalized and distributed primarily in the intracellular membranes of the
endoplasmic reticulum (ER) and Golgi apparatus and to a lesser extent in the mitochondria
(82). Cumulatively, these findings suggest that a novel target for OSW-1 other than
NCX1/OSBP may exist in these subcellular sites and merits further investigation.
Gangliosides are constituents of the glycosphingolipid-enriched microdomains (GEM
or rafts) in the cell membrane, where they play a pivotal role in mediating cell proliferation,
invasion and adhesion signaling (17, 19). Previous investigations provide evidence that
ganglioside synthesis occurs intracellularly in the golgi complex and the ‘mitochondriaassociated membrane’ (MAM) compartment of the endoplasmic reticulum through a
glycosylation process regulated by glycosyltransferases, including GD3 synthase, a resident
Golgi protein (161, 162). Specifically, the ganglioside GD3 plays a paradigmatic role,
wherein, in contrast to its cell proliferative function, it also acts as a cell death effector
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through its intracellular translocation to the mitochondria during stress conditions, leading to
cytochrome c release, ROS generation and cell killing (143, 144, 146).
Our results demonstrate that OSW-1 inhibits ganglioside GD3 in melanoma cells by
repressing gene expression of the enzyme, GD3 synthase (ST8SIA1 gene), which catalyzes
the biosynthesis of ganglioside GD3 from its precursor GM3 by addition of a second sialic
acid residue (163, 164). Consequently we observed a moderate decrease in ganglioside GD3,
a more significant inhibition of its downstream product, GD2 and an accumulation of the
precursor GM3 (figure 3.11). Importantly, this inhibition of ganglioside GD2 correlated with
the cell death effect (represented by MMP) of OSW-1 in melanoma cells (figure 3.19).
Nevertheless, it is unresolved if GD3S is a direct target for OSW-1 in melanoma.
Interestingly, the OSW-1 structural analog, Triptolide, induced down regulation of human
GD3 synthase (hST8SIA1) gene expression through NF-κB activation in melanoma cells
(56). In addition, the transcription factor TWIST and GNE kinase are also known to
positively regulate GD3S expression (165, 166). Therefore, it might be important to examine
the effect of OSW-1 on signaling transduction proteins that are upstream of GD3 synthase.
Another key protein that may potentially be a cellular interacting target of OSW-1 is the
steroid regulatory element binding protein (SREBP), which acts as a master transcription
factor regulating cholesterol and fatty acid biosynthesis (167). Prior structure-activity
relationship studies demonstrated that the steroid nucleus in OSW-1’s structure was critical
to its potent cytotoxic effect (66, 72). The SREBP protein, because of its ability to bind to
sterol regulatory elements (168), may form a putative binding partner of OSW-1. Further,
OSW-1 treatment inhibits expression of lipogenesis genes, FASN and HMGCR, which are
downstream targets of SREBP. Cumulatively, these results point towards the possibility of
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SREBP being a direct target of OSW-1 in melanoma cells. My future studies will be directed
towards characterizing the molecular binding target(s) of OSW-1, with a strong focus on
SREBP. Please refer to chapter 5(summary and future directions) for a detailed description of
my experimental plans for this aspect of the OSW-1 future study.VDAC1 is a multifunctional
channel protein involved in mitochondria dependent cell death, redox metabolism, and
cancer cell signaling. It has been implicated in cell death induction by stimuli such as
cisplatin, curcumin, myostatin, UV irradiation and oxidative stress through either homooligomerization or interaction with Bcl-2 family proteins, adenine nucleotide translocase
(ANT), regulation of Ca2+ and ATP flux, or ROS detoxification (169, 170). Our original
results demonstrated that OSW-1 induced interaction between ganglioside GD3 and VDAC1
in the mitochondrial membranes (figure 3.17, 3.18). Hence we characterized the effect of
OSW-1 on VDAC1 expression and VDAC1 dependent cell death signaling in melanoma.
Our data indicated that OSW-1 caused VDAC1 upregulation, increased cytosolic calcium
and mitochondrial superoxide release in melanoma cells (figures 3.20, 3.23, 3.24).
Interestingly, Triptolide, which inhibits GD3S, also activated VDAC1expression (figure
3.22). Nevertheless, combination of OSW-1 with the VDAC inhibitor, DIDS, did not affect
OSW-1 mediated ganglioside GD3/GD2 inhibition (figure 3.30), thus suggesting that GD3S
might regulate VDAC1 expression but not vice versa. Significantly, combination of OSW-1
with the immunosuppressant drug, cyclosporin A, not only upregulated VDAC1 expression
but also led to elevated cell death (figure 3. 26 A, 3.25). Considering that combination
therapy with cyclosporine has been known to improve clinical efficacy in advanced
malignancies, we propose that this OSW-1+CsA treatment strategy may improve the
therapeutic benefit of OSW-1 in melanoma and thus merits further investigation (171, 172).
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Finally, knock out or knock down of VDAC1 ameliorated the cytotoxic effect of OSW-1 in
melanoma (figure 3.28, 3.29), thus corroborating our findings that VDAC1 and mitochondria
dependent cell death mechanisms are crucial to the antineoplastic activity of OSW-1.
Increased expression of gangliosides GD3 and GM3 in melanoma cell lines and
tissues, and a correlation between GD3 expression levels and the GD3 synthase enzymatic
activity in cells has been reported (53, 54, 173). This is obvious in the comparison between
melanoma cells and normal melanocytes wherein the melanocytes exhibit extremely low
GD3 synthase activity and GD3 cell surface expression (16). Based on this information, we
postulated that differential ganglioside expression profile may form a basis for the
therapeutic selectivity of OSW-1 towards melanoma cells with limited toxicity to normal
melanocytes (figure 3.9, 3.10). To test this hypothesis, we compared the basal ganglioside
expression pattern between the OSW-1 resistant WM35DW and the parental WM35 cells
(figure 3.32). Our results indicate WM35DW cells have a reduced GD3 and GD2 expression
than the parental WM35 cells. A decreased free radical expression profile was also observed
in the resistant WM35DW cells (figure 3.33). RPPA analysis revealed altered expression of
multiple lipid metabolism proteins including FASN, YAP, FAK and caveolin-1 in WM35 vs.
WM35DW cells (figure 3.35 A, B). Differential expression of mitochondrial signaling
proteins such as VDAC1, cyclophilin and various interacting partners of VDAC1 such as
Bcl-2 family members, and GSK3 was also observed (figure 3.35 A, C). Further
investigation into the molecular mechanisms regulating GD3 synthase activity and the cell
signaling regulating VDAC1-GD3 interaction may provide deeper insights into the
therapeutic basis for the selective elimination of melanoma cells by OSW-1.
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In summary, our study delineates the mechanisms essential to the highly potent
anticancer activity of OSW-1 in melanoma cells. Our results demonstrate that OSW-1
induces autophagic cell death in melanoma by repressing GD3 synthase gene expression,
leading to inhibition of gangliosides GD3, GD2 and accumulation of GM3. Ganglioside GD3
then interacts with the mitochondrial VDAC1 leading to mitochondrial membrane potential
collapse, aberrant calcium signaling and cell death. VDAC1 is a critical player in mediating
OSW-1’s activity as its down regulation confers resistance to OSW-1. A significant
characteristic of OSW-1 induced cytotoxicity is its therapeutic selectivity towards melanoma
cells. Our investigation reveals that elevated ganglioside expression in melanoma may form
the basis for the increased sensitivity of these cells towards OSW-1. To our knowledge, this
is the first study to demonstrate the antitumor effect of OSW-1 on ganglioside expression and
VDAC1 mediated mitochondrial signaling in melanoma. The role of OSW-1 as an inhibitor
of GD3 synthase gene expression is crucial, since in melanoma ganglioside GD3 is a well
characterized therapeutic target. Therefore, further research needs to be undertaken to shed
light on the mechanisms regulating this GD3 synthase inhibition by OSW-1.
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Chapter 4: PEITC effectively eliminates melanoma cells through redox mechanisms
4.1: Introduction
PEITC is a highly active metabolite of cruciferous vegetables with potent
chemopreventive and chemotherapeutic properties. It inhibits expression of pro-oncogenic
proteins such as Bcl-2, Mcl1 and Bcl-xL, triggers cell cycle arrest, DNA and mitochondrial
damage leading to caspase activation, cytochrome c release and apoptosis (95, 98).
PEITC exhibits a unique mechanism of cell death – it induces excessive ROS
accumulation in cancer cells leading to massive cytotoxicity (63, 64, 94). This ROS induced
toxicity by PEITC is specific to tumor cells; normal melanocytes with a lower basal oxidative
stress phenotype and reserve antioxidant capacity are resistant to PEITC and other prooxidant compounds (63).
In this dissertation, I investigated the mechanisms of cytotoxic action and therapeutic
selectivity of PEITC in melanoma cells. I aimed to characterize the differences in redox
status between the normal cells and cancer cells and use this as a mechanistic basis to
specifically eliminate melanoma cells. My results demonstrate the PEITC depletes cellular
glutathione in melanoma cells leading to ROS stress, loss of mitochondrial membrane
potential and cell death through apoptosis. Further, a positive correlation between the basal
cellular ROS expression levels and sensitivity to PEITC was observed. Accordingly, normal
melanocytes which have a much lower intrinsic oxidative stress compared to melanoma cells
are resistant to PEITC. The glutathione depletion mediated by PEITC is an early event which
occurs much before cell death and is crucial to the cytotoxic effect of PEITC in melanoma.
Due to this distinctive mechanism of cell death, PEITC is effective in attenuating drug
resistance to clinically used melanoma agents.
94

4.2 Results
4.2.1 Redox status of melanoma cells
A characteristic feature of melanoma biology is the presence of aberrant
melanosomes in melanoma cells that generate free radicals (174). Chronic oxidative stress
potentiated by oncogenic Akt signaling or loss of tumor suppressors such as p53 and p16, in
combination with exposure to ultraviolet radiations (UV), UVA and UVB, may lead to
oncogenic transformation of dysplastic nevi and development of an intrinsic drug resistant
phenotype in melanoma cells (44, 62, 175-177). On the other hand, excessive reactive
oxygen species (ROS) accumulation in melanoma cells leads to massive toxicity and cell
death, thus making it a unique therapeutic target. Hence, I hypothesized that melanoma cells
are under elevated intrinsic oxidative stress and can be preferentially eliminated by
pharmacological agents such as PEITC which modulate the cellular redox homeostasis.
To investigate this hypothesis, we first characterized the basal redox status of
melanoma cells. The intracellular free radical expression levels were determined across a
panel of melanoma cells by flow cytometric analysis using the fluorescent reagents, CM-H2DCFDA,

DAF-FM

and

dihydroethidium.

5-,6-Chloromethyl-2’7’-

Dichlorodihydrofluorescein Diacetate (CM-H2-DCFDA) is an indicator of hydroxyl radicals,
peroxides and other ROS molecules in cells. DCFDA passively diffuses into the cells, where
its acetate groups are cleaved by intracellular esterases and the compound is subsequently
oxidized to yield the fluorescent 2’7’-Dichlorofluorescein (DCF), which can be detected by
flow cytometry (178). 4-Amino-5-Methylamino-2', 7’-Difluorofluorescein (DAF-FM)
detects nitric oxide (NO) in cells. The non-fluorescent DAF-FM reacts with intracellular NO
and is converted into the fluorescent benzotriazole molecule which can be quantified (179).
Dihydroethidium (Het) is a blue fluorescent dye which is oxidized by superoxides to form
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oxiethidium, which then intercalates with nucleic acids to emit a bright red fluorescence that
can be detected by flow cytometry or microscopy (180).
Our results indicated that Hs294T (BRAF WT, metastatic) melanoma cells had the
highest expression of basal ROS and nitric oxide (figure 4.1 A, B, D). Superoxide levels
were elevated across the melanoma cells evaluated in this study. Overall, SK-MEL-2 (BRAF
WT, NRAS Q617R, metastatic) cells contained relatively higher free radical expression
among the melanoma cells tested (figure 4.1). The A375SM (BRAF V600E, NRAS WT,
highly metastatic) cells had a moderately decreased free radical expression profile compared
to the other melanoma cells (figure 4.1). Hence, SK-MEL-2 and A375SM cells were used as
representative cell line models in the follow-up mechanistic studies.
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Figure 4.1: Basal free radical expression profile in melanoma cells.
(A), (B), (C) Melanoma cells were plated in 6-well plates for 24 h prior to the measurement
of cellular reactive oxygen species, nitric oxide and superoxides using the fluorescent probes
DCFDA, DAF-FM and Dihydroethidium by flow cytometry. (D) Mean count of the basal
reactive oxygen species, nitric oxide and superoxide expression levels in melanoma cells.

97

4.2.2 The cytotoxic effect of PEITC in melanoma
Earlier studies from our lab demonstrated that the natural product, PEITC was
effective in inhibiting leukemia cells including fludarabine resistant chronic lymphocytic
leukemia and Gleevec-resistant chronic myelogenous leukemia (63, 102). To investigate the
effect of PEITC on melanoma cell viability, I performed an MTT assay across a panel of cell
lines treated with varying concentrations of PEITC for 72 h. As illustrated in figure 4.2,
PEITC was cytotoxic to melanoma cells with an average half-maximal inhibitory
concentration (IC50) of 2.21 µM. Interestingly, WM46 cells which have the lowest levels of
basal ROS expression amongst all the melanoma cells tested (figure 4.1D), also have the
highest IC50 value (4.10 µM; figure 4.2B).
Biochemical analysis by annexin V-FITC/propidium iodide staining indicated that
PEITC induced apoptosis in melanoma cells in a time dependent fashion (figure 4.3A, B).
PEITC induced cell death was detectable at 12 h and reached over 70% by 24 h in A375SM
and SK-MEL-2 cells (figure 4.3A). The bar graphs in figure 4.3B represent the heterogeneity
of melanoma cell response to PEITC. On average, a 24 h PEITC treatment caused 55.73%
(DMSO vs. PEITC 24h, p-value < 0.0001) cell death in melanoma cells. Significantly,
combination of PEITC with the pan caspase inhibitor, Z-VAD-FMK, partially rescued
melanoma cells from the cytotoxic effect of PEITC (figure 4.3C). Caspases are a group of
intracellular proteases that play a pivotal role during apoptosis by catalyzing the disassembly
of cells into membrane-enclosed vesicles (apoptotic bodies), ultimately leading to death
(181). Treatment of SK-MEL-2 cells with 5 µM PEITC induced 71.74% cell killing.
However, co-treatment of cells with 20 µM Z-VAD-FMK and 5 µM PEITC reduced cell
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death to 30.23% (figure 4.3C). These results delineate the role of caspase activation and
apoptosis in mediating the inhibitory activity of PEITC.
Figure 4.2:
A
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Figure 4.2: Effect of PEITC on melanoma cell viability
Melanoma cells were treated with log-scale serial diluted concentrations of PEITC for 72 h,
and the cytotoxic effect was determined by performing the MTT assay. The cell viability
curves were plotted. Each data point represents mean ± SEM for three independent
measurements. (B) The 50% cell inhibitory concentrations (IC50) of PEITC for each cell line
are indicated.
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Figure 4.3: PEITC induced cytotoxicity is through apoptosis in melanoma cells
(A) SK-MEl-2 and A375SM cells were treated with 10 µM PEITC for the indicated time
points and PEITC induced cell death induced was detected by annexin V-FITC/PI staining
and flow cytometric analysis as described in materials and methods. (B) Percent cell viability
of melanoma cells treated with 10 µM PEITC for the indicated time points. Bar graphs
represent mean ± SEM of three independent measurements. (C) SK-MEL-2 cells incubated
in 20 µM Z-VAD-FMK for 1 h were treated with 5 µM PEITC for 24 h and cell death was
measured by flow cytometric analysis (annexin V-FITC/PI staining). **** denotes p <
0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05.
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Mitochondrial dysfunction constitutes an important event in the induction of cell
death. Opening of the mitochondrial transition pore leading to depolarization of membrane
potential, release of apoptogenic proteins and uncoupling of oxidative phosphorylation have
been linked to apoptosis stimulation by agents such as tert-Butylhydroperoxide, the calcium
ionophore A23187, selenite, sulforaphane etc. (182-186). To test if PEITC caused
mitochondrial membrane damage in melanoma, I treated the cells with 5 µM PEITC for
varying time points and the effect on mitochondrial membrane integrity was assessed by flow
cytometric analysis of cells labeled with Rhodamine 123, a lipophilic, cationic fluorescent
dye that is readily taken up by active mitochondria. Depolarization of the mitochondrial
membrane, therefore, decreases the mitochondrial rhodamine 123 signal, which can be
quantified (187). My results indicate that PEITC potentiated a time-dependent mitochondrial
membrane potential collapse in SK-MEL-2 and A375SM cells (figure 4.4). Mitochondrial
membrane permeabilization was first observed at 16 h and by 24 h there was a massive (over
90%) loss of membrane potential in PEITC treated cells as compared to the DMSO treated
controls (DMSO vs. PEITC 24h, p-value < 0.0001).
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Figure 4.4:
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Figure 4.4: PEITC induces mitochondrial membrane potential loss in melanoma cells.
A375SM and SK-MEL-2 cells were treated with 5 µM PEITC for the indicated time points
and the effect on mitochondrial membrane potential was evaluated by flow cytometric
analysis of Rhodamine 123 labelled cells.

103

Figure 4.5:
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Figure 4.5: Correlation between cellular basal ROS levels and cell death induced by
PEITC.
Cellular intrinsic ROS expression levels were measured by performing the DCFDA assay.
Cell death was detected by annexin V-FITC/PI assay in melanoma cells treated with 10 µM
PEITC for 24 h. Linear regression analysis between these two parameters was performed
using the mean ± SEM measurements of three independent experiments.
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Figure 4.6: Effect of PEITC on JNK and p38 expression in melanoma.
SK-MEL-2 cells were treated with 5 µM PEITC for the indicated time points and the effect
on JNK and p38 kinase expression was assessed by western blotting.
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Quantitative evaluation of the relationship between basal cellular ROS levels and
PEITC induced cell death revealed a strong correlation between these two parameters (r =
0.8068, p-value = 0.0155) (figure 4.5). ROS have been known to promote apoptotic signaling
by mediating the activation of pro-apoptotic JNK and ASK1 kinases, leading to upregulation
of TNFα, Fas-L and Bak, release of cytochrome C, and mitochondrial translocation of Bax
and Bad apoptotic proteins (188-191). Interestingly, western blot analysis indicated that
PEITC stimulated a time-dependent increase in phosphorylated-JNK expression in SKMEL2 cells (figure 4.6). However, no significant change was observed in the expression of
total JNK as well as total and phosphorylated p38 MAP kinase (figure 4.6). Collectively
these results indicate that PEITC executes its anticancer effect through apoptosis and ROS
mediated mechanisms in melanoma cells. Of significance is the observation that the basal
ROS status of melanoma cells is proportional to its sensitivity to PEITC.
4.2.3 PEITC exhibits minimal toxicity in normal melanocytes
The promising cytotoxic activity of PEITC in melanoma cells led us to investigate the
effect of this compound on normal melanocyte cell viability. As shown in figure 4.7, normal
melanocytes were significantly less sensitive to PEITC compared to melanoma cells.
Annexin-FITC/PI analysis demonstrated that a 24 h PEITC treatment caused 60% cell death
in melanoma cells (n = 9), while 94.73% of normal melanocytes were still viable at this time
point (figure 4.7B). Interestingly, PEITC stimulated massive cytotoxicity in HS294T (figure
4.7A) and SK-MEL-2 (figure 4.3A) melanoma cells, which have a relatively higher ROS
capacity. Previous research findings have shown that PEITC mediated cell death is
characterized by ROS production either though depletion of the glutathione antioxidant
system or inhibition of oxidative phosphorylation in leukemia, ovarian and prostate cancers
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(63, 64, 113). This led me to speculate that the anticancer effect of PEITC relied on
disrupting on the cellular redox homeostasis leading to ROS accumulation and subsequent
toxicity. As expected, incubation of SK-MEL-2 cells with 5 µM PEITC for 8 h resulted in
substantial ROS accumulation, whereas only a slight increase in ROS levels was observed in
normal melanocytes (figure 4.8). These results suggest that distinct redox regulatory
mechanisms exist between melanoma cells and normal melanocytes and these may form the
basis for their differential response to PEITC.
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Figure 4.7:
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Figure 4.7: Preferential killing of melanoma cells by PEITC
(A) Cell death induced by 10 µM PEITC in melanoma cells and normal melanocytes was
determined by flow cytometric analysis of annexin V-FITC/PI stained cells. Representative
dot blots are shown here. (B) Bar graphs illustrate the quantitative comparison of PEITC
triggered cell death (normalized to DMSO control) in melanoma (n = 9) and normal
melanocyte cells at 24 h treatment. Mean ± SEM of cell death measurements from three
independent experiments of each melanoma cell line and normal melanocytes is denoted
here. ** denotes p < 0.01.
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Figure 4.8:

NHEM

SK-MEL-2

8h
DMSO

8h
DMSO

Figure 4.8: Induction of ROS accumulation in melanoma cells and normal melanocytes
by PEITC.
SK-MEL-2 cells and normal melanocytes were treated with 5 µM PEITC for 8 h and ROS
levels were detected by flow cytometric analysis of cells labelled with 1 µM DCFDA.
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Figure 4.9:
A

*

B
SK-MEL-2
NHEM

C

D
**

SK-MEL-2
NHEM

Figure 4.9: Comparison of ROS expression between melanoma cells and normal
melanocytes.
(A) and (C) Flow cytometric analysis to detect ROS (DCFDA) and specifically
superoxides (Dihydroethidium) was performed in SK-MEL-2 and normal melanocytes
(NHEM) stained with 1 µM DCFDA and Dihydroethidium. (B) and (D) Bar graphs
represent the mean ± SEM of ROS and superoxide measurements from three independent
experiments of each melanoma cell line (n = 8) and normal melanocytes. ** denotes p <
0.01 and * denotes p< 0.05.
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The preferential ROS accumulation in melanoma cells treated with PEITC suggested
that these cells were under increased intrinsic oxidative stress thus making them more
vulnerable to further free radical elevation and redox disturbance by PEITC. To evaluate this
observation, I compared the basal ROS and specifically superoxide expression levels
between melanoma cells and normal melanocytes. As illustrated in figure 4.9 A and B,
melanoma cells exhibit increased ROS expression compared to normal melanocytes (P-value
< 0.05). SK-MEL-2 cells had a 2.3 fold increased intrinsic ROS expression compared to
normal melanocytes (figure 4.9A). Importantly, the intrinsic superoxide levels were 3-fold
higher (p-value < 0.01) in melanoma cells than the normal melanocytes (figure 4.9D). A
representative histogram indicating the differential superoxide expression in melanoma cells
is shown in figure 4.9C. Based on these results, I concluded that the higher intrinsic oxidative
stress observed in melanoma cells was important in modulating their sensitivity to PEITC.
4.2.4 The ROS mediated mechanisms of cell death by PEITC
Treatment of SK-MEL-2 and A375SM cells with 5 µM PEITC produced a time
dependent increase in cellular ROS levels (figure 4.10B). A 6 h PEITC incubation of SKMEL-2 cells increased cellular ROS levels by 3.2-fold (figure 4.10A). In contrast, PEITC (10
µM, 8 h) did not induce any significant ROS change in normal melanocytes (figure 4.8),
suggesting that this ROS elevation rendered the melanoma cells susceptible to PEITC’s
cytotoxic activity. Interestingly, flow cytometric analysis of melanoma cells stained with
Dihydroethidium indicated that PEITC treatment did not generate any significant change in
the cellular superoxides (O2¯ ) (figure 4.10D), although the intrinsic superoxide expression
was significantly increased in melanoma cells compared to normal melanocytes (figure 4.9
C, D). PEITC stimulated a time dependent increase in nitric oxide levels (figure 4.10C).
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Figure 4.10:
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Figure 4.10: Effective killing of melanoma cells through ROS induced damage
(A), (C) and (D): SK-MEL-2 cells were treated with 5µM PEITC for the indicated time
points and alterations in ROS, nitric oxide and superoxide expression in cells was assessed
by DCFDA, DAF-FM and dihydroethidium staining. (B) A375SM and SK-MEL-2 cells were
treated with 10µM PEITC for a varying time course and DCFDA assay was performed. ***
denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05.
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Cumulatively, these results suggest that PEITC induced ROS may include other
molecules such as hydrogen peroxide, hydroxyl radical and nitric oxide but not superoxides.
This data corroborates with previous findings from our lab in oncogenic Ras transformed
ovarian epithelial cells (T72 Ras) where PEITC induced ROS and NO generation, without
any significant changes in O2¯ (113). Further, the relationship between ROS accretion and
PEITC mediated toxicity was quantitatively evaluated by plotting PEITC induced cell death
as a function of ROS increase (figure 4.11). A positive correlation (r = 0.7357, p-value <
0.05) between these two factors was observed.
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Figure 4.11:
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Figure 4.11: Correlation between cell death and PEITC induced ROS stress
Cell death was detected by annexin V-FITC/PI assay in melanoma cells treated with 10 µM
PEITC for 24 h. ROS expression levels in PEITC treated melanoma cells were measured by
DCFDA assay. Cell death was plotted as a function of ROS fold change and linear regression
analysis was performed.
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Since PEITC triggered cell death was characterized by ROS accumulation in cells, I
next investigated the potential cause for this ROS stimulation by PEITC. Glutathione is a
major antioxidant which has been shown to promote metastatic melanoma cell survival in the
hepatic microvasculature by protecting the cells against oxidative stress induced damage
(192). Importantly, glutathione depletion either by pharmacological intervention using LButhionine (S, R)-Sulphoximine (BSO) or by dietary modulation using an L-glutamine
enriched diet reduced melanoma tumor growth and sensitized cells to combination therapy
(192, 193). Further, studies by Trachootham et al., and Lam et al., indicated that PEITC
scavenges glutathione in leukemia and breast cancer cells leading to massive cytotoxicity
(93, 113). I postulated that the high ROS capacity in malignant melanoma cells would make
them dependent upon the glutathione antioxidant system to maintain redox balance in cells,
and therefore depletion of glutathione by PEITC would disrupt the redox homeostasis
resulting in excessive ROS accumulation, beyond the cell’s tolerance threshold, and
subsequent cell death. To examine this hypothesis, I treated SK-MEL-2 and A375SM cells
with 5 µM PEITC for 3 and 6 h and detected the cellular glutathione levels (figure 4.12).
PEITC induced inhibition of glutathione was detected at 3 h and by 6 h about 60% of cellular
glutathione was depleted. It is important to note that PEITC treatment exhibits limited
cytotoxicity at these time durations (figure 4.3B), suggesting that this glutathione depletion
may be a primary event that potentiates ROS accumulation and consequent cell death. To
verify this possibility, I treated SK-MEL-2 and A375SM cells pre-incubated in the
glutathione precursor, N-Acetyl Cysteine (NAC) with PEITC (figure 4.13). As shown in
figure 4.13 A and B, NAC reverses the ROS elevation caused by PEITC. More importantly,
combination of NAC with PEITC completely abrogates the cytotoxic effect of PEITC in SK-
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MEL-2 cells (figure 4.13C). Hence glutathione depletion is an important mechanism in
PEITC induced ROS increase and cell death.

Figure 4.12:
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Figure 4.12: PEITC causes depletion of cellular glutathione.
A375SM and SK-MEL-2 cells were treated with 5 µM PEITC for the indicated time points
and cellular glutathione levels were detected by spectrophotometric analysis as described in
materials and methods. ** denotes a statistical significance of p < 0.01 between the DMSO
control and PEITC treated samples in each of the respective cell lines .
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Figure 4.13: N-Acetyl Cysteine (NAC) reverses the inhibitory effect of PEITC
(A) SK-MEL-2 cells incubated in 1 mM NAC for 2 h were treated with 5 µM PEITC for 6 h
and ROS were detected by the DCFDA assay. (B) Bar graphs denote the mean ± SEM of
three independent measurements of ROS in A375SM and SK-MEL-2 cells treated with
PEITC ± NAC. (C) Annexin V-FITC/PI assay was performed to detect the effect on cell
death in SK-MEL-2 cells treated with PEITC ± NAC for 24 h. **** denotes p < 0.0001 and
*** denotes p < 0.001.
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4.2.5 Combination of Temozolomide / BCNU with PEITC attenuates drug resistance to
these agents in melanoma
Malignant melanomas are characterized by significant drug resistance to currently
used chemotherapeutic agents such as Temozolomide (TMZ) and 1,3-bis-(2-chloroethyl)-1nitrosourea (BCNU). Interestingly, BCNU has been shown to inhibit glutathione reductase
activity in erythrocytes from patients as well as in mouse liver, lung and heart tissues (194,
195). Further, Kohsaka et al. demonstrated that combination of TMZ with the glutathione
synthesis inhibitor, BSO, potentiated the toxic effect of Temozolomide in TMZ resistant
glioblastoma cells (196). Based on this information, I postulated that combination of PEITC
with either BCNU or TMZ would cause incremental oxidative stress due to an enhanced
depletion of cellular glutathione. This would lead to significant toxicity in melanoma cells
and would be of therapeutic benefit. Towards this end, I first performed annexin V-FITC/PI
assay to examine the effect of PEITC ± TMZ/BCNU combination on cell death in melanoma
cells (figure 4.14). The results indicate that supplementation of PEITC with either BCNU or
TMZ promoted significantly higher inhibitory effect than that of any (PEITC/TMZ/BCNU)
single agent treatment. The cytotoxic effect of this drug combination was evaluated by
performing the colony formation assay. As illustrated in figure 4.15, PEITC, BCNU or TMZ
as a single agent moderately inhibited colony formation (figure 4.15 A, C). However,
combination of TMZ/BCNU with PEITC caused a striking decrease in the number of
colonies formed. For instance, PEITC+BCNU treatment potentiated 3.5-fold decrease in the
number of colonies as compared to PEITC single agent treatment (figure 4.15B).
Furthermore, combination index (CI) analysis using the Chou-Talalay algorithm was
performed to characterize the type of drug interaction (figure 4.16). SK-MEL-2 cells were
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incubated with varying combination regimens of PEITC (5 µM, 10 µM and 20 µM; last 24 h)
and BCNU (50 µM, 100 µM and 200 µM; 48 h) or TMZ (0.3 mM, 0.6 mM and 1 mM; 48 h).
As described in figure 14.6B, the combination of PEITC with TMZ was synergistic (CI<1.0).
Similarly, BCNU and PEITC combination index analysis mostly produced synergistic and
additive (CI=1) end points (figure 4.16D).
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A

B

P=0.113
*

*

**
***

*

*

**
**

**

P=0.231
P=0.157
****
*
***
***

*
****

**
****

Figure 4.14: Effect of PEITC ± TMZ/BCNU treatment on melanoma cell viability
SK-MEL-2 and A375SM cells were incubated in varying concentrations of BCNU and TMZ
for 48 h. During the last 24 h of treatment 5 µM PEITC was added and the effect of the drug
combination on cell death was determined by annexin V-FITC/propidium iodide staining.
Bar graphs represent the percentage of viable cells in each drug treatment sample as a
function of the DMSO treated control cell viability. **** denotes p < 0.0001, *** denotes p
< 0.001, ** denotes p < 0.01 and * denotes p< 0.05.
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Figure 4.15: Combination of Temozolomide / BCNU with PEITC inhibits colony
formation in melanoma cells
(A) and (C) A375P cells were treated with the indicated concentrations of PEITC and
BCNU/TMZ for 2 weeks and the effect of the drug combination on colony formation was
determined by Giemsa staining. (B) and (D) The colonies formed were counted manually and
have been represented as bar graphs. *** denotes p < 0.001, ** denotes p < 0.01 and *
denotes p< 0.05.
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Figure 4.16:
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Figure 4.16: Combination index analysis of PEITC ± TMZ/BCNU treatment
(A) and (C) Representative dot blots indicating cell death induced by TMZ ± PEITC and
BCNU ± PEITC 48 h treatment in SK-MEL-2 cells. PEITC was added during the last 24 h of
treatment. (B) and (D) SK-MEL-2 cells were treated with the indicated concentrations of
PEITC ± TMZ/BCNU for 48 h, and combination index (CI) analysis was performed using
Compusyn software. The following quantitative definitions, based on the Chou-Talalay
theorem, were employed to define combination effect: CI < 1 represents synergism, CI = 1
represents an additive effect, and CI > 1 represents antagonism.
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Figure 4.17:
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Figure 4.17: Redox mechanisms mediate the combinatorial cell death effect of TMZ/
BCNU ± PEITC treatment in melanoma.
(A) Melanoma cells were treated with 0.5 mM TMZ for 24 h. 5 µM PEITC was added during
the last 6 h of treatment. ROS, nitric oxide and mitochondrial superoxides were measured by
DCFDA, DAF-FM and mitosox red staining and flow cytometric analysis. (B) 5 µM PEITC
was added during the last 3h of a 24 h 100 µM BCNU or 0.5mM TMZ treatment. Bar graphs
represent mean ± SEM of cellular glutathione measurements for the indicated drug
concentrations in three independent experiments. * denotes p< 0.05.
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To delineate the mechanisms that are pivotal to this increased cytotoxicity of
PEITC+TMZ/BCNU drug combination in melanoma cells, we analyzed for changes in redox
expression in cells treated with PEITC ± TMZ/BCNU. Co-treatment of PEITC (5 µM, 6 h)
with TMZ (0.5 mM, 24 h) led to increased ROS and nitric oxide generation as compared to
the effect of PEITC as a single agent (figure 4.17A, B). Also, Temozolomide, by itself, did
not induce any significant changes in ROS. Further, this combination (PEITC+TMZ) also
stimulated a slightly increased generation of mitochondrial superoxides as detected by the
mitosox red indicator (figure 4.17C). Importantly, this ROS increase was preceded by
glutathione depletion in SK-MEL-2 cells. Addition of 5 µM PEITC to melanoma cells preincubated in BCNU or TMZ led to inhibited cellular glutathione. The glutathione depletion
was higher in combinatorial treatment of PEITC+BCNU/TMZ as compared to a single agent.
Thus, glutathione depletion forms a primary event in attenuating drug resistance to TMZ or
BCNU in melanoma using the redox modulating agent, PEITC.
In conclusion, the natural product PEITC exhibits significant anticancer activity in
melanoma. Its inhibitory effects in melanoma are mediated by ROS accumulation and
disabling of the glutathione antioxidant system.
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4.3 Discussion
Reactive oxygen species have been long known to promote melanoma development,
metabolism and metastasis (38). However, the utility of ROS as a therapeutic target is yet to
be characterized. Earlier studies in our lab revealed that pharmacologically induced ROS
accumulation effectively eliminated cancer cells (61, 113). In this study, I demonstrate that
the redox modulatory agent, PEITC selectively kills melanoma cells based on their
differential intrinsic oxidative stress status as compared to normal melanocytes. Melanoma
cells are under an elevated ROS stress and therefore, are dependent upon antioxidants to
maintain redox balance. This makes them vulnerable to therapeutic agents that impair the
cellular antioxidant system, leading to ROS accumulation and massive cytotoxicity. Normal
melanocytes, on the other hand, are less susceptible to this strategy since they have a lower
basal ROS expression and so any additional oxidative stress induced by pharmacological
agents is still within the cells’ tolerance threshold. This biochemical difference between
normal and cancer cells may be used to selectively eliminate melanomas.
The key conclusions from this study are: (a) PEITC is highly cytotoxic to melanoma
cells with limited toxicity in normal melanocytes (figure 4.7). (b) Melanoma cells are under
higher intrinsic oxidative stress compared to normal melanocytes (figure 4.9). Basal ROS
expression levels of melanoma cells positively correlate with their sensitivity to PEITC
(figure 4.5). (c) The elevated oxidative stress renders melanomas sensitive to PEITC which
depletes the antioxidant glutathione, leading to severe ROS accumulation, mitochondrial
membrane damage, activation of JNK kinase and rapid apoptotic cell death (figure 4.3, 4.4,
4.6, 4.10, 4.12). In contrast, PEITC causes modest ROS increase in normal melanocytes,
which is not significant enough to promote cell death (figure 4.8). Consequently, these cells
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are resistant to PEITC. (d) Inhibition of cellular glutathione by PEITC is a critical event since
the glutathione precursor, NAC, reverses ROS accumulation as well as PEITC mediated cell
death (figure 4.13). Furthermore, glutathione depletion can be detected much earlier than cell
death suggesting that it is a primary event that instigates ROS elevation and PEITC induced
toxicity in melanoma (figure 4.12). (e) Combination of PEITC with BCNU/TMZ ameliorates
drug resistance to these agents in melanoma (figure 4.14, 4.16). Higher glutathione depletion,
ROS accumulation and consequent cell death is observed in the samples treated with
PEITC+BCNU/TMZ as compared to single agent treated samples (figure 4.17).
Trachootham et al. and Xu et al. demonstrated that PEITC disabled glutathione in
leukemia cells by two mechanisms: conjugating with glutathione, thus promoting its export
from the cells and inhibiting Glutathione Peroxidase (GPX) activity (100, 113). Interestingly,
incubation of cells with 5 – 10 µM PEITC caused inhibition of glutathione in the mM range
(113). A possible explanation for this stochiometric discrepancy may be that PEITC is
concentrated at higher concentrations in cells. Indeed, incubation of the oncogenic T72Ras
cells with 5 - 10 µM PEITC for 2 h led to intracellular concentrations of 0.25 – 0.59 mM.
Subsequent biochemical analysis indicated that 0.5 mM PEITC suppressed GPX activity by
over 90% in a cell-free enzyme assay. These data suggest that PEITC at µM concentrations,
used in cell culture assays, may deplete the cellular glutathione pool and GPX enzyme
activity significantly leading to ROS accumulation and cytotoxicity. PEITC mediated
inhibition of oxidative phosphorylation and mitochondrial damage leading to ROS generation
in leukemia and prostate cancer has also been reported (64, 94).

Furthermore, PEITC

potentiated activation of JNK kinase in DU145 prostate cancer cells (197). Interestingly, this
PEITC-induced apoptosis was attenuated by pharmacological inhibition of JNKs with
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SP600125 suggesting that JNK activation was critical to PEITC’s activity in these cells
(197). Stress induced activation of ERK1/2 was also observed. JNK proteins play a crucial
role in regulating cytochrome C release and apoptosis induction following UV irradiation in
MEF cells (198). JNK kinases have also been reported to activate apoptotic signaling by
modulating the expression of pro-apoptotic and anti-apoptotic mitochondrial proteins (188,
199, 200). PEITC causes a time dependent increased JNK phosphorylation in melanoma cells
(figure 4.6). Considering that PEITC triggers apoptosis through mitochondrial membrane
permeabilization and caspase activation (figure 4.3, 4.4), it is plausible that JNK proteins
may be instrumental in mediating this cell death process. Further studies, using either
inhibitors or siRNAs to downregulate JNK expression need to be undertaken to delineate the
role of JNK in effecting PEITC’s cytotoxic activity in melanoma cells.
PEITC potentiated ROS accumulation in cells was detected by DCFDA and DAF-FM
fluorescent probes but not by HEt suggesting that the free radicals activated by PEITC were
mostly peroxides, hydroxyl radicals and nitric oxide but not superoxides (figure 4.10).
Nevertheless, the basal superoxide expression in melanoma cells is significantly higher than
normal melanocytes (figure 4.9C, D). This may be because of the rapid conversion of
superoxides to hydrogen peroxide, peroxynitrites etc (201, 202).
A recent study by Vazquez et al. (2013), demonstrated that the transcriptional coactivator, PGC1α, promoted increased mitochondrial energy metabolism and ROS
detoxification capacities in melanoma (203). Consequently, depletion of PGC1α in these
cells sensitized them to ROS-inducing drugs such as PEITC and Piperlongumine (203).
These results suggest that redox modulation therapies might be especially useful for the
subset of melanomas which are PGC1α negative. Further, combining PGC1α inhibition with
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ROS accretion (using PEITC or other ROS inducing agents) might be another strategy to
increase drug sensitivity in PGC1α positive tumors. The mutant BRAF inhibitor,
Vemurafenib promoted mitochondrial respiration and elevated ROS stress in BRAF V600E
melanoma cells irrespective of their PGC1α status (204). Further, vemurafenib-resistant cells,
generated by treating the parental A375, SKMEL28 and WM9 melanoma cells with
increasing concentrations of vemurafenib, exhibited high mitochondrial activity and intrinsic
oxidative stress compared to the parental cells (204). Importantly, the vemurafenib-resistant
cells were more sensitive to pro-oxidative drugs such as Elesclomal and PEITC than the
parental cells (204). Thus redox mediated cell death strategies find increasing utility in
melanoma chemotherapy either as a single agent or in combination with currently used
clinical melanoma drugs including vemurafenib.
Recent studies reported that activation of oncogenes such as K-Ras and Akt in an
inducible system led to an elevated intrinsic oxidative stress phenotype in cells (112, 205).
Hence, cancer cells with these specific oncogene activations may be especially susceptible to
ROS inducing agents. Nogueira et al., through in vitro and in vivo studies demonstrated that
using PEITC (as a single agent or in combination with Rapamycin) in cancer cells with Akt
activation may constitute a strategy to selectively inhibit these cells (205). This therapeutic
scheme may be of significant utility in melanomas where 20% tumors exhibit PTEN loss
leading to increased basal Akt activation (39).
My results indicate that combination of PEITC with either BCNU or TMZ had a
synergistic cell death effect (figure 4.16). The cytotoxicity of this drug combination was
mediated by redox mechanisms wherein PEITC + TMZ treatment led to significantly higher
glutathione depletion and ROS accumulation compared to that of a single agent treatment of
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either PEITC or TMZ (figure 4.17). Glutathione efflux pumps (GS-X) play a major role in
resistance to various chemotherapeutic inhibitors such as cisplatin, temozolomide,
carmustine and other alkylating agents, daunorubicin and natural products (206, 207). The
drug resistance mediated by GS-X pumps directly correlates with the cellular glutathione or
glutathione S- transferase (GST) levels and involves two mechanisms (a) formation of GSHS drug conjugate (b) exclusion of this GSH-S drug conjugate from the cell by the GS-X
export carrier pump (208, 209). Incidentally, the glutathione synthesis inhibitor, BSO has
been reported to partially reverse this GS-X pump induced drug resistance to alkylating
agents in lung tumor cell lines (210). Previous reports have indicated that PEITC conjugates
with glutathione causing its export from the cell (100). Hence, I propose that PEITC
mediated export of glutathione by GS-X pumps would inhibit the exclusion of BCNU and
TMZ from the cells. This would sensitize the cells to the DNA alkylating effects of
Temozolomide/BCNU, trigger ROS elevation and subsequently cause cell death. Further
investigation needs to be undertaken to shed light on the mechanisms that direct the
synergistic combinatorial effect of PEITC+TMZ/BCNU in melanoma. These studies may
constitute the future perspectives of this project.
In conclusion, my research on the anticancer effects of PEITC in melanoma cells
presents a novel strategy to selectively kill melanoma cells based on the differential redox
biology between normal melanocytes and melanoma cells. PEITC scavenges glutathione
antioxidant system leading to ROS accumulation and cytotoxicity in melanomas. This unique
mechanism of action of PEITC and other glutathione inhibitors such as BSO can be used to
combat resistance to other chemotherapeutic agents such as Temozolomide, BCNU and
Vemurafenib.
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Chapter 5: Summary and future directions
5.1 Summary
My PhD dissertation outlines two novel therapeutic strategies to effectively eliminate
melanoma cells with limited toxicity to normal melanocytes.
The saponin molecule, OSW-1 is highly cytotoxic to melanoma cells with halfmaximal inhibitory concentrations in the sub-nanomolar range. It induces autophagic cell
death in melanoma cells by repressing the gene expression of GD3 synthase enzyme, leading
to inhibition of gangliosides GD3, GD2 and accumulation of GM3. Ganglioside GD3 is
overexpressed in melanoma cells and is a well characterized therapeutic target. OSW-1 also
promotes co-localization of ganglioside GD3 with the mitochondrial voltage dependent anion
channel 1 (VDAC1) protein. This causes VDAC1 upregulation, mitochondrial membrane
permeabilization, superoxide release and loss of calcium homeostasis leading to cell death.
The elevated GD3 and GD2 expression in melanoma cells may be the basis of therapeutic
selectivity of OSW-1 against melanoma cells since the normal melanocytes as well as the
OSW-1 resistant, WM35 DW cells exhibit a decreased basal GD3 and GD2 expression.
Further studies need to be undertaken to identify the direct cellular binding target of OSW-1.
Studies also need to focus on delineating the mechanisms of selectivity of OSW-1.
The natural product PEITC relies on the redox differences between normal and cancer
cells to selectively eliminate cancer cells. In my study, I first characterized the basal ROS
and RNOS expression status of melanoma cells and normal melanocytes. I observed that the
sensitivity of melanoma cells to PEITC correlated with the basal ROS expression status of
the cells. Normal melanocytes with reduced intrinsic oxidative stress were resistant to
PEITC. PEITC induced ROS accumulation and glutathione depletion in melanoma cells.
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Glutathione depletion occurred much before cell death. Supplementing the cells with the
glutathione precursor, NAC, reversed the ROS accumulation and apoptosis mediated by
PEITC. This indicates that the glutathione depletion is an important mechanism to PEITC
induced cytotoxicity. Further, drug combination of PEITC with TMZ or BCNU ameliorates
the chemoresistance to these agents. Future studies will focus on investigating oxidative
stress based strategies to combat drug resistance in melanoma.
5.2 Future directions
5.2.1 Mechanisms of selectivity of OSW-1 and PEITC against malignant melanoma cells
Mechanisms of selectivity of OSW-1 towards melanoma cells:
An important feature of OSW-1 mediated cell death was its selectivity against
melanoma cells with minimal toxicity to normal melanocytes. I generated OSW-1 resistant
WM35 (WM35 DW) cells (figure 3.31) to characterize the mechanisms underlying this
therapeutic selectivity of OSW-1. My results indicate that WM35DW cells have a reduced
basal ganglioside GD3 and GD2 expression profile compared to the parent WM35 cells
(figure 3.32). This ganglioside expression pattern is similar to normal melanocytes which
express only trace amounts of the pro-oncogenic ganglioside GD3 but prominent levels of
the tumor suppressive ganglioside GM3 (16). OSW-1 inhibits GD3 by repressing gene
expression of the enzyme GD3 synthase. Previous reports demonstrated an elevated
expression of GD3 Synthase (GD3S) in melanoma compared to other cancers (173). Further,
the initial NCI-60 cell line panel in vitro screening identified that melanoma cells (exhibit
ganglioside GD3 overexpression) were more sensitive to OSW-1 than the other cell lines
tested (67). Hence, I speculate that the differential ganglioside GD3 expression in normal

133

melanocytes compared to melanoma cells may form the basis for the selectivity of OSW-1
against malignant melanoma cells.
In order to test this possibility, I would perform ganglioside GD3 overexpression
experiments in normal melanocytes. I hypothesize that if GD3 mediated signaling is critical
to executing the cytotoxic activity of OSW-1, then overexpressing GD3 in normal
melanocytes by transfecting them with the GD3S gene would sensitize these cells to OSW-1.
For this purpose, GD3 deficient SK-Mel-28 cells (referred as N1) as well as the GD3
synthase overexpressing G5 and G11 cell clones that were established from N1 cells would
serve as valuable cell models (17, 211). If the GD3 expression status of the cell governs its
sensitivity to OSW-1, then the N1 cells would be resistant to OSW-1 whereas the G5 and
G11 SK-MEL-28 cells would exhibit increased sensitivity to OSW-1. I hope to initiate
collaborations to acquire these cells and test them for the cytotoxic effect of OSW-1.
VDAC1 was a critical effector molecule in mediating the cell death effect of OSW-1.
RPPA results showed that the OSW-1 resistant WM35 DW cells exhibited a lower basal
expression of VDAC 1 and VDAC1 interacting proteins such as Bcl-2 and GSK-3 (figure
3.35 A, C). Further the VDAC1 knock out MEF cells (MEF VDAC1-/-) and siVDAC1
transfected A375SM melanoma cells were resistant to OSW-1 (figure 3.28, 3.29). Hence, I
think it is important to compare the basal VDAC1 expression levels across melanoma cell
lines and the normal melanocytes and investigate if there is a correlation between VDAC1
expression status and sensitivity to OSW-1. It would be worthwhile to perform VDAC1
transfection experiments in normal melanocytes to examine if induced expression of VDAC1
would sensitize these cells to OSW-1.
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Finally OSW-1 mediated cell death in melanoma cells is through autophagy.
Inhibition of autophagy by using pharmacological inhibitors or down regulating the
expression of autophagy genes abrogates OSW-1 induced cell death (figure 3.6). Hence, I
would investigate normal melanocytes and melanoma cells to ascertain if differences in
intrinsic autophagy flux (as indicated by expression of p62, Beclin-1, Atg5, Atg 8) and
mitochondrial mass between the cells contributes to their sensitivity to OSW-1.
Mechanisms of melanoma cell selectivity of PEITC:
PEITC inhibited prostate and leukemia cancer growth by disrupting mitochondrial
oxidative phosphorylation (OXPHOS) leading to ATP depletion and ROS production (64,
94). Further, ROS generation in was an early, upstream event that contributed to DNA
fragmentation, collapse of mitochondrial membrane potential, cytochrome c release and
apoptosis. Interestingly, this ROS production and other downstream events such as caspase
activation and mitochondrial membrane damage were not observed in the OXPHOS deficient
Rho-0 prostate cancer cells, indicating that oxidative stress were a crucial mechanism
regulating the selectivity circuitry of PEITC (64). Similar results were observed in my study
wherein ROS generation was observed much before cell death and normal melanocytes were
resistant to free radical induction by PEITC. This ROS accumulation in melanoma cells was
partly due to glutathione depletion. My next step would be to investigate the molecular
mechanisms that promote ROS elevation in melanoma cells. Towards this end, my focus will
be two-fold: investigate effect of PEITC on (a) mechanisms regulating glutathione
biosynthesis and metabolism (b) mitochondrial respiration and the respiratory complex
activity.
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(a) Glutathione synthesis is a 2-step process: γ-glutamyl cysteinyl synthetase (GCS) enzyme
first catalyzes the generation of γ-glutamyl cysteine from cysteine and glutamate. Second, the
glutathione synthetase enzyme combines γ-glutamyl cysteine and glycine to produce
glutathione (GSH) (212). The availability of cysteine is the rate limiting step in this process
(212, 213). The balance between reduced (GSH) and oxidized (GSSG) forms of glutathione
in the cell is maintained by the enzymes glutathione peroxidase (GPX) and glutathione
reductase (GR). Previous research from our lab indicated that PEITC inhibited glutathione
peroxidase activity thus potentiating hydrogen peroxide accumulation in cells (113). First I
would perform enzyme activity assays to determine if PEITC treatment abrogates the activity
of GPX, GR, GCS and glutathione synthetase enzymes. The fact that supplementation of
NAC reverses the cell death effect of PEITC (figure 4.13C) suggests that PEITC may not be
inhibiting the activity of enzymes that catalyze glutathione biosynthesis (i.e. GCS and
glutathione synthetase). After having identified the putative target enzyme modulated by
PEITC, I would then examine the effect of PEITC on this target enzyme expression and
activity in melanoma cells vs. normal melanocytes.
(b) To examine the effect of PEITC on oxidative phosphorylation, I would employ the
Seahorse Bioscience XF24 extracellular flux analyzer to compare oxygen consumption rate,
and reserve respiration capacity in normal melanocytes and melanoma cells (both basal levels
and PEITC induced changes). I would then use metabolic inhibitors such as oligomycin, 2Deoxy glucose, rotenone and carbonyl cyanide p-trifluoromethoxyphenyl hydrazone (FCCP)
to determine the effect of PEITC on each of the mitochondrial respiratory complex activity.
Simultaneously, I would perform western blots to test the effect of PEITC on mitochondrial
respiratory complex (es) expression in both normal melanocytes and melanoma cells.
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I believe that this two-fold approach to characterizing the mechanisms that regulate
PEITC induced ROS accumulation in melanoma cells vs. normal melanocytes will provide
insights into the selectivity of PEITC towards melanoma cells.
5.2.2 Characterization of the direct molecular target for OSW-1: SREBP and GD3S
regulatory signaling pathways
My PhD dissertation research demonstrates that OSW-1 represses the gene expression
of GD3 synthase enzyme in melanoma cells. However, it remains unclear if GD3 Synthase is
the direct target of OSW-1. The fact that OSW-1 inhibits GD3S gene expression points
towards the possibility that OSW-1 may potentially interact/bind with a protein (such as a
transcription factor) that is upstream of GD3 synthase signaling pathway and regulates its
expression. Recent studies demonstrated that GD3 expression in melanoma cells correlated
with activation of the steroid regulatory element binding protein (SREBP) leading to
increased expression of HMGCR and elevated cholesterol biosynthesis (10). Burgett et al.
(2011), through affinity chromatography and quantitative mass spectrometry approaches in
HeLa-S3 cell lysate treated with the OSW-1 affinity reagent (prepared by covalently linking
OSW-1 analogue to sepharose) identified the oxysterol binding protein (OSBP) as a cellular
binding target of OSW-1 (69). However, the authors in this study did not explore the
functional significance (such as effect on downstream proteins, signaling pathways etc.) of
this interaction between OSW-1 and OSBP; nor did they prove that this interaction was
imperative to mediating the cytotoxic effect of OSW-1. More importantly, shRNA mediated
knockdown of OSBP expression did not exhibit a cytotoxicity profile similar to OSW-1
treatment of cells, suggesting that there may be other molecular binding targets for OSW-1.
Yamada et al. (2014), using fluorescent OSW-1 demonstrated that the putative binding
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targets of OSW-1 could be located in the ER and golgi apparatus since the fluorescent OSW1 molecule localized with high affinity to these organelles in the cell (82). Based on these
studies and my own research results I postulate that OSW-1 potentially interacts with a
ganglioside or lipid signaling protein which is primarily located in the ER/golgi apparatus of
the cell.
SREBP is a master transcription factor regulating cholesterol and fatty acid
biosynthesis (167). The premature and mature forms of SREBP reside in the ER and golgi
apparatus, before being cleaved by serine proteases and transported to the nucleus (214).
Further, SREBP expression correlates with GD3 expression status of the cell (10). Hence, I
plan to investigate if OSW-1 directly interacts with SREBP in melanoma cells. Below I
outline the experimental approaches I would employ to test this hypothesis.
(a) I would perform Chromatin Immunoprecipation (ChIP) for SREBP binding DNA
elements in the control and OSW-1 treated cells. I would then perform real time-PCR
experiment with the ChIP output DNA product to detect the expression of SREBP target
genes including FASN and HMGCR. If OSW-1 directly interacted with SREBP, then the
expression of FASN and HMGCR genes would be suppressed in the OSW-1 treated samples.
(b) Biotinylated OSW-1 (75) will be used for this experimental design. Streptavidin magnetic
beads (Solulink, San Diego, CA) may be used to isolate proteins that bind to biotinylated
OSW-1 in an experimental design similar to affinity chromatography. Gel electrophoresis
and quantitative mass spectrometry will then be performed with the product protein sample
from the streptavidin beads-biotinylated OSW-1 pull down assay to identify the interaction
partners of OSW-1, including SREBP-1.

138

The second approach of using the streptavidin beads-biotinylated OSW-1 pull down
assay (similar design as affinity chromatography) will be extremely useful in identifying the
interaction protein partners of OSW-1. It would also be important to determine the effect of
OSW-1 on the expression of GD3 synthase expression regulatory proteins such as TWIST,
UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE), and amyloid precursor protein (APP)
by immunoprecipitation, streptavidin beads-biotinylated OSW-1 pull down assay and
western blotting (165, 166, 215).

5.2.3 Oxidative stress based strategies to combat drug resistance in melanoma using
PEITC
My results demonstrate that combination of PEITC with either TMZ or BCNU
induces a synergistic drug cytotoxic effect. This increased cell death due to
PEITC+TMZ/BCNU co-treatment in melanoma cells was characterized by enhanced
depletion of glutathione and consequent ROS accumulation in cells. Prior studies have shown
BCNU inhibits glutathione reductase in blood cells (194). My results indicate that treatment
of melanoma cells with 100 µM BCNU or 0.5 mM TMZ for 24 h causes modest glutathione
inhibition. However, supplementation of PEITC (5 µM) during the last 3 h triggered
significant glutathione depletion. Glutathione impairment occurred much earlier than cell
death implying that it is an important mechanism regulating the anticancer effect of PEITC ±
BCNU/TMZ drug combination in melanoma cells. I postulate that PEITC would promote
increased cytotoxicity in TMZ/BCNU treated cells due to its ability to conjugate with and
export GSH out of the cell thus limiting drug resistance to TMZ/BCNU by Glutathione efflux
pumps. This in combination with inhibition of GR by BCNU may lead to a higher cell death.
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To test this possibility, I would examine intracellular as well as culture media concentrations
of glutathione and PEITC after PEITC ± TMZ/BCNU treatments in melanoma cells.
Furthermore, I would also investigate the effect of TMZ/BCNU/PEITC treatment on
GPX/GR enzyme activity in melanoma cells.
ROS generation and ERK1/2-mediated protective autophagy has been reported to
cause resistance to Temozolomide in glioblastoma cells (216, 217). I propose that
combination of PEITC with TMZ/BCNU would push the ROS generation triggered by these
alkylating agents beyond the cell’s tolerance levels leading to massive toxicity. Figure 4.17
A, B and C describes that PEITC + BCNU/TMZ treatment causes elevated ROS, nitric oxide
and mitochondrial superoxide generation. Of specific interest is the induction mitochondrial
superoxide by this drug combination. Inhibition of oxidative phosphorylation may cause
superoxide accumulation in the mitochondria. Hence I would perform western blot as well as
use Seahorse Bioscience XF24 extracellular flux analyzer to investigate the effect of PEITC
+ TMZ/BCNU drug combination on mitochondrial respiration and oxygen consumption.
Finally, I would test the efficacy of this PEITC + TMZ/BCNU drug combination in vivo
using athymic nude mice. Khor et al., demonstrated that i.p. injections of PEITC (2.5 µmol,
3X per week) and curcumin (3 µmol, 3X per week) in human PC-3 prostate xenografts in
immunodeficient mice significantly reduced tumor growth (218). I propose to test the effect
of PEITC ± TMZ/BCNU in immunodeficient mice inoculated with A375SM cells with
optimized drug dosage and treatment times.
Recent studies have indicated that the clinical mutant BRAF inhibitor, vemurafenib,
causes ROS stress in melanoma cells (204). Combination of vemurafenib with ROS inducing
agents might be a worthwhile strategy to eliminate these tumors. Important PEITC may be
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effective in killing vemurafenib resistant tumors since these are characterized by elevated
intrinsic oxidative stress compared to the vemurafenib sensitive melanomas.
Both OSW-1 and PEITC induced cell death is characterized by elevations in ROS
levels and mitochondria dependent mechanisms of action. Hence it will be worthwhile to
characterize the combinatorial drug effect of OSW-1 and PEITC in melanoma cells. In this
study, the effect of OSW-1 + PEITC combination on various molecular markers such as
glutathione, mitochondrial VDAC1, gangliosides GD3 and GD2, nitric oxide and
superoxides will be examined. It may be crucial to be compare and correlate the basal
expression and drug induced changes of these markers in a particular cell line to its
sensitivity to OSW-1+PEITC treatment. This type of analysis will be of clinical significance
as it may lead to the identification of biomarkers that would predict patient response to this
combinatorial OSW-1+PEITC drug treatment strategy.
Therapeutic

selectivity

is

an

important

characteristic

of

any

successful

pharmacological agent. In this dissertation, I elucidate the mechanisms of anticancer activity
and therapeutic selectivity of two novel inhibitors, OSW-1 and PEITC. OSW-1 exerts its
antiproliferative effect by inhibiting ganglioside GD3 expression and causing VDAC1
activation, subsequently leading to acute autophagy. PEITC relies on the differential redox
biology between the cancer cells and normal melanocytes to preferentially eliminate
melanoma cells. Both OSW-1 and PEITC employ relatively novel therapeutic strategies to
effectively eliminate malignant melanomas and warrant further testing in pre-clinical and
clinical settings.
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